The use of DRUGS to treat a DISEASE or its symptoms. One example is the use of ANTINEOPLASTIC AGENTS to treat CANCER.
Therapy with two or more separate preparations given for a combined effect.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION).
Those persons legally qualified by education and training to engage in the practice of pharmacy.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Formal programs for assessing drug prescription against some standard. Drug utilization review may consider clinical appropriateness, cost effectiveness, and, in some cases, outcomes. Review is usually retrospective, but some analysis may be done before drugs are dispensed (as in computer systems which advise physicians when prescriptions are entered). Drug utilization review is mandated for Medicaid programs beginning in 1993.
Drugs used to prevent SEIZURES or reduce their severity.
Total pharmaceutical services provided by qualified PHARMACISTS. In addition to the preparation and distribution of medical products, they may include consultative services provided to agencies and institutions which do not have a qualified pharmacist.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
Directions written for the obtaining and use of DRUGS.
Total pharmaceutical services provided to the public through community pharmacies.
Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.
The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
An antiepileptic agent related to the barbiturates; it is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite. Adverse effects are reported to be more frequent than with PHENOBARBITAL. (From Martindale, The Extra Pharmacopoeia, 30th ed, p309)
Insurance providing for payment of services rendered by the pharmacist. Services include the preparation and distribution of medical products.
Health insurance plans intended to reduce unnecessary health care costs through a variety of mechanisms, including: economic incentives for physicians and patients to select less costly forms of care; programs for reviewing the medical necessity of specific services; increased beneficiary cost sharing; controls on inpatient admissions and lengths of stay; the establishment of cost-sharing incentives for outpatient surgery; selective contracting with health care providers; and the intensive management of high-cost health care cases. The programs may be provided in a variety of settings, such as HEALTH MAINTENANCE ORGANIZATIONS and PREFERRED PROVIDER ORGANIZATIONS.
Agents that are used to treat hyperthyroidism by reducing the excessive production of thyroid hormones.
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
Voluntary cooperation of the patient in following a prescribed regimen.
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
Educational programs designed to inform graduate pharmacists of recent advances in their particular field.
The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.
A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
Substances that suppress Mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.
Directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery.
A sympathomimetic that acts mainly by causing release of NOREPINEPHRINE but also has direct agonist activity at some adrenergic receptors. It is most commonly used as a nasal vasoconstrictor and an appetite depressant.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Assistance in managing and monitoring drug therapy for patients receiving treatment for cancer or chronic conditions such as asthma and diabetes, consulting with patients and their families on the proper use of medication; conducting wellness and disease prevention programs to improve public health; overseeing medication use in a variety of settings.
Organic compounds that contain GOLD as an integral part of the molecule. Some are used as ANTIRHEUMATIC AGENTS. The term chrysotherapy derives from an ancient Greek term for gold.
A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
The return of a sign, symptom, or disease after a remission.
Societies whose membership is limited to pharmacists.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
Removal of tissue with electrical current delivered via electrodes positioned at the distal end of a catheter. Energy sources are commonly direct current (DC-shock) or alternating current at radiofrequencies (usually 750 kHz). The technique is used most often to ablate the AV junction and/or accessory pathways in order to interrupt AV conduction and produce AV block in the treatment of various tachyarrhythmias.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Elements of limited time intervals, contributing to particular results or situations.
A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.
Substances used to lower plasma CHOLESTEROL levels.
Economic aspects of the fields of pharmacy and pharmacology as they apply to the development and study of medical economics in rational drug therapy and the impact of pharmaceuticals on the cost of medical care. Pharmaceutical economics also includes the economic considerations of the pharmaceutical care delivery system and in drug prescribing, particularly of cost-benefit values. (From J Res Pharm Econ 1989;1(1); PharmacoEcon 1992;1(1))
Agents that promote the excretion of urine through their effects on kidney function.
Dynamic and kinetic mechanisms of exogenous chemical and DRUG LIBERATION; ABSORPTION; BIOLOGICAL TRANSPORT; TISSUE DISTRIBUTION; BIOTRANSFORMATION; elimination; and DRUG TOXICITY as a function of dosage, and rate of METABOLISM. LADMER, ADME and ADMET are abbreviations for liberation, absorption, distribution, metabolism, elimination, and toxicology.
The use of multiple drugs administered to the same patient, most commonly seen in elderly patients. It includes also the administration of excessive medication. Since in the United States most drugs are dispensed as single-agent formulations, polypharmacy, though using many drugs administered to the same patient, must be differentiated from DRUG COMBINATIONS, single preparations containing two or more drugs as a fixed dose, and from DRUG THERAPY, COMBINATION, two or more drugs administered separately for a combined effect. (From Segen, Dictionary of Modern Medicine, 1992)
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Services providing pharmaceutic and therapeutic drug information and consultation.
Hospital department responsible for the receiving, storing, and distribution of pharmaceutical supplies.
Therapeutic approach tailoring therapy for genetically defined subgroups of patients.
A subtype of epilepsy characterized by seizures that are consistently provoked by a certain specific stimulus. Auditory, visual, and somatosensory stimuli as well as the acts of writing, reading, eating, and decision making are examples of events or activities that may induce seizure activity in affected individuals. (From Neurol Clin 1994 Feb;12(1):57-8)
A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Voluntary cooperation of the patient in taking drugs or medicine as prescribed. This includes timing, dosage, and frequency.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
The teaching or training of patients concerning their own health needs.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes drug stockpiling, and patient drug profiles.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
An imidazole antithyroid agent. Carbimazole is metabolized to METHIMAZOLE, which is responsible for the antithyroid activity.
An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of PHENYTOIN; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar.
Drugs whose drug name is not protected by a trademark. They may be manufactured by several companies.
One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.
Review of claims by insurance companies to determine liability and amount of payment for various services. The review may also include determination of eligibility of the claimant or beneficiary or of the provider of the benefit; determination that the benefit is covered or not payable under another policy; or determination that the service was necessary and of reasonable cost and quality.
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). (From Adams et al., Principles of Neurology, 6th ed, p329)
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
Endogenous factors or drugs that increase the transport and metabolism of LIPIDS including the synthesis of LIPOPROTEINS by the LIVER and their uptake by extrahepatic tissues.
A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
The expected function of a member of a particular profession.
Provisions of an insurance policy that require the insured to pay some portion of covered expenses. Several forms of sharing are in use, e.g., deductibles, coinsurance, and copayments. Cost sharing does not refer to or include amounts paid in premiums for the coverage. (From Dictionary of Health Services Management, 2d ed)
Works about lists of drugs or collections of recipes, formulas, and prescriptions for the compounding of medicinal preparations. Formularies differ from PHARMACOPOEIAS in that they are less complete, lacking full descriptions of the drugs, their formulations, analytic composition, chemical properties, etc. In hospitals, formularies list all drugs commonly stocked in the hospital pharmacy.
Method in which prolonged electrocardiographic recordings are made on a portable tape recorder (Holter-type system) or solid-state device ("real-time" system), while the patient undergoes normal daily activities. It is useful in the diagnosis and management of intermittent cardiac arrhythmias and transient myocardial ischemia.
A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
Drugs that are used to treat RHEUMATOID ARTHRITIS.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
Patterns of practice related to diagnosis and treatment as especially influenced by cost of the service requested and provided.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Pregnane derivatives containing three double bonds in the ring structures.
Extensive collections, reputedly complete, of facts and data garnered from material of a specialized subject area and made available for analysis and application. The collection can be automated by various contemporary methods for retrieval. The concept should be differentiated from DATABASES, BIBLIOGRAPHIC which is restricted to collections of bibliographic references.
The giving of drugs, chemicals, or other substances by mouth.
Conformity in fulfilling or following official, recognized, or institutional requirements, guidelines, recommendations, protocols, pathways, or other standards.
Errors in prescribing, dispensing, or administering medication with the result that the patient fails to receive the correct drug or the indicated proper drug dosage.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
A traditional grouping of drugs said to have a soothing or calming effect on mood, thought, or behavior. Included here are the ANTI-ANXIETY AGENTS (minor tranquilizers), ANTIMANIC AGENTS, and the ANTIPSYCHOTIC AGENTS (major tranquilizers). These drugs act by different mechanisms and are used for different therapeutic purposes.
Conditions with excess LIPIDS in the blood.
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
Regulation of the rate of contraction of the heart muscles by an artificial pacemaker.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
Information systems, usually computer-assisted, designed to store, manipulate, and retrieve information for planning, organizing, directing, and controlling administrative activities associated with the provision and utilization of clinical pharmacy services.
Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
Autoantibodies that bind to the thyroid-stimulating hormone (TSH) receptor (RECEPTORS, THYROTROPIN) on thyroid epithelial cells. The autoantibodies mimic TSH causing an unregulated production of thyroid hormones characteristic of GRAVES DISEASE.
Substances that reduce or suppress INFLAMMATION.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.
Persistent pain that is refractory to some or all forms of treatment.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
An electrical current applied to the HEART to terminate a disturbance of its rhythm, ARRHYTHMIAS, CARDIAC. (Stedman, 25th ed)
A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
The study of the origin, nature, properties, and actions of drugs and their effects on living organisms.
The actual costs of providing services related to the delivery of health care, including the costs of procedures, therapies, and medications. It is differentiated from HEALTH EXPENDITURES, which refers to the amount of money paid for the services, and from fees, which refers to the amount charged, regardless of cost.
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
A broad approach to appropriate coordination of the entire disease treatment process that often involves shifting away from more expensive inpatient and acute care to areas such as preventive medicine, patient counseling and education, and outpatient care. This concept includes implications of appropriate versus inappropriate therapy on the overall cost and clinical outcome of a particular disease. (From Hosp Pharm 1995 Jul;30(7):596)
Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE.
Substances which lower blood glucose levels.
A generic expression for any tachycardia that originates above the BUNDLE OF HIS.
Implantable devices which continuously monitor the electrical activity of the heart and automatically detect and terminate ventricular tachycardia (TACHYCARDIA, VENTRICULAR) and VENTRICULAR FIBRILLATION. They consist of an impulse generator, batteries, and electrodes.
Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
Reduction of pharmacologic activity or toxicity of a drug or other foreign substance by a living system, usually by enzymatic action. It includes those metabolic transformations that make the substance more soluble for faster renal excretion.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of voltage dependent sodium channels.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Reductions in all or any portion of the costs of providing goods or services. Savings may be incurred by the provider or the consumer.
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
Formal instruction, learning, or training in the preparation, dispensing, and proper utilization of drugs in the field of medicine.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
The prediction or projection of the nature of future problems or existing conditions based upon the extrapolation or interpretation of existing scientific data or by the application of scientific methodology.
A class of chemicals derived from barbituric acid or thiobarbituric acid. Many of these are GABA MODULATORS used as HYPNOTICS AND SEDATIVES, as ANESTHETICS, or as ANTICONVULSANTS.
The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level.
Abnormally rapid heartbeats originating from one or more automatic foci (nonsinus pacemakers) in the HEART ATRIUM but away from the SINOATRIAL NODE. Unlike the reentry mechanism, automatic tachycardia speeds up and slows down gradually. The episode is characterized by a HEART RATE between 135 to less than 200 beats per minute and lasting 30 seconds or longer.
The veins that return the oxygenated blood from the lungs to the left atrium of the heart.
A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.
The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine.
A small nodular mass of specialized muscle fibers located in the interatrial septum near the opening of the coronary sinus. It gives rise to the atrioventricular bundle of the conduction system of the heart.
An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.
Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.
Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.
A benzimidazole broad-spectrum anthelmintic structurally related to MEBENDAZOLE that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment.
Societies whose membership is limited to physicians.
Substances that are destructive to protozoans.
Criteria and standards used for the determination of the appropriateness of the inclusion of patients with specific conditions in proposed treatment plans and the criteria used for the inclusion of subjects in various clinical trials and other research protocols.
An approach of practicing medicine with the goal to improve and evaluate patient care. It requires the judicious integration of best research evidence with the patient's values to make decisions about medical care. This method is to help physicians make proper diagnosis, devise best testing plan, choose best treatment and methods of disease prevention, as well as develop guidelines for large groups of patients with the same disease. (from JAMA 296 (9), 2006)
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
A direct-acting vasodilator that is used as an antihypertensive agent.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Techniques for measuring blood pressure.
Organized systems for providing comprehensive prepaid health care that have five basic attributes: (1) provide care in a defined geographic area; (2) provide or ensure delivery of an agreed-upon set of basic and supplemental health maintenance and treatment services; (3) provide care to a voluntarily enrolled group of persons; (4) require their enrollees to use the services of designated providers; and (5) receive reimbursement through a predetermined, fixed, periodic prepayment made by the enrollee without regard to the degree of services provided. (From Facts on File Dictionary of Health Care Management, 1988)
Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time.
The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time.
A device designed to stimulate, by electric impulses, contraction of the heart muscles. It may be temporary (external) or permanent (internal or internal-external).
A cytochrome P450 enzyme that catalyzes the hydroxylation of many drugs and environmental chemicals, such as DEBRISOQUINE; ADRENERGIC RECEPTOR ANTAGONISTS; and TRICYCLIC ANTIDEPRESSANTS. This enzyme is deficient in up to 10 percent of the Caucasian population.
Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.
A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
Compounds capable of relieving pain without the loss of CONSCIOUSNESS.
Agents that prevent clotting.
Agents destructive to parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal.
A systematic statement of policy rules or principles. Guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by convening expert panels. The text may be cursive or in outline form but is generally a comprehensive guide to problems and approaches in any field of activity. For guidelines in the field of health care and clinical medicine, PRACTICE GUIDELINES AS TOPIC is available.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or "seizure disorder."
Research aimed at assessing the quality and effectiveness of health care as measured by the attainment of a specified end result or outcome. Measures include parameters such as improved health, lowered morbidity or mortality, and improvement of abnormal states (such as elevated blood pressure).
Patient or client refusal of or resistance to medical, psychological, or psychiatric treatment. (APA, Thesaurus of Psychological Index Terms, 8th ed.)

Prednisone in MOPP chemotherapy for Hodgkin's disease. (1/16029)

High remission rates have been produced by MOPP (mustine, vincristine, procarbazine, and prednisone) chemotherapy in patients with advanced Hodgkin's disease, but the prednisone component has caused adverse effects in patients who have undergone radiotherapy. The remission rates and length of remission were reviewed in 211 patients with Hodgkin's disease who received chemotherapy either with or without prednisone. In contrast to the findings of a British study, there were no significant differences in remission rates or length of remission between patients who had received prednisone and patients who had not. There were differences between the British prospective study and this retrospective one, but it is difficult to know what accounted for the substantial differences in the findings.  (+info)

Double-blind intervention trial on modulation of ozone effects on pulmonary function by antioxidant supplements. (2/16029)

The aim of this study was to investigate whether the acute effects of ozone on lung function could be modulated by antioxidant vitamin supplementation in a placebo-controlled study. Lung function was measured in Dutch bicyclists (n = 38) before and after each training session on a number of occasions (n = 380) during the summer of 1996. The vitamin group (n = 20) received 100 mg of vitamin E and 500 mg of vitamin C daily for 15 weeks. The average ozone concentration during exercise was 77 microg/m3 (range, 14-186 microg/m3). After exclusion of subjects with insufficient compliance from the analysis, a difference in ozone exposure of 100 microg/m3 decreased forced expiratory volume in 1 second (FEV1) 95 ml (95% confidence interval (CI) -265 to -53) in the placebo group and 1 ml (95% CI -94 to 132) in the vitamin group; for forced vital capacity, the change was -125 ml (95% CI -384 to -36) in the placebo group and -42 ml (95% CI -130 to 35) in the vitamin group. The differences in ozone effect on lung function between the groups were statistically significant. The results suggest that supplementation with the antioxidant vitamins C and E confers partial protection against the acute effects of ozone on FEV1 and forced vital capacity in cyclists.  (+info)

Epidemiology of drug-resistant tuberculosis in Texas. (3/16029)

During 1987-1996, over 22,000 tuberculosis cases were reported in Texas, at an average annual incidence rate of 12.5 cases per 100,000 population. Counties with the highest rates were located along the Mexico-Texas border and in northwestern Texas. Nine percent of cases were resistant to at least one of the five first-line antituberculosis drugs used for treatment. Almost 5 percent (4.6%) were resistant to isoniazid, either alone or in combination with other antibiotics; 2.3% were resistant to rifampin; and only 1.3% were resistant to both isoniazid and rifampin. Being a recurrent case, being foreign-born, being 20-39 years of age, and residing in a Mexico-Texas border county were independent risk factors for isoniazid resistance and rifampin resistance. Tuberculosis patients with human immunodeficiency virus (HIV) infection were more likely to have rifampin resistance and less likely to have isoniazid resistance than patients without HIV infection. Factors associated with multi-drug-resistant tuberculosis included a history of previous tuberculosis (relative risk (RR) = 4.91, 95% confidence interval (CI) 3.5-6.8), non-US birth (RR = 2.69, 95% CI 2.1-3.5), age younger than 20 years (RR = 1.97, 95% CI 1.1-3.5), age 20-39 years (RR = 1.82, 95% CI 1.3-2.6), and residence in a Mexico-Texas border county (RR = 2.33, 95% CI 1.8-3.1).  (+info)

In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. (4/16029)

Isolated perfusion of the extremities with high-dose tumour necrosis factor alpha (TNF-alpha) plus melphalan leads to dramatic tumour response in patients with irresectable soft tissue sarcoma or multiple melanoma in transit metastases. We developed in vivo isolated organ perfusion models to determine whether similar tumour responses in solid organ tumours can be obtained with this regimen. Here, we describe the technique of isolated kidney perfusion. We studied the feasibility of a perfusion with TNF-alpha and assessed its anti-tumour effects in tumour models differing in tumour vasculature. The maximal tolerated dose (MTD) proved to be only 1 microg TNF-alpha. Higher doses appeared to induce renal failure and a secondary cytokine release with fatal respiratory and septic shock-like symptoms. In vitro, the combination of TNF-alpha and melphalan did not result in a synergistic growth-inhibiting effect on CC 531 colon adenocarcinoma cells, whereas an additive effect was observed on osteosarcoma ROS-1 cells. In vivo isolated kidney perfusion, with TNF-alpha alone or in combination with melphalan, did not result in a significant anti-tumour response in either tumour model in a subrenal capsule assay. We conclude that, because of the susceptibility of the kidney to perfusion with TNF-alpha, the minimal threshold concentration of TNF-alpha to exert its anti-tumour effects was not reached. The applicability of TNF-alpha in isolated kidney perfusion for human tumours seems, therefore, questionable.  (+info)

Clinical experience and choice of drug therapy for human immunodeficiency virus disease. (5/16029)

To determine if providers experienced in the management of human immunodeficiency virus (HIV) disease preferred different treatment regimens than providers with less experience, we analyzed data from a national survey of primary care providers' preferred regimens for the management of 30 HIV-related medical conditions. We mailed questionnaires to 999 correct addresses of providers in > 20 cities in the United States in May 1996. We received 524 responses (response rate, 52%). We found a statistically significant association between the number of HIV-infected patients cared for by the provider and the likelihood that the provider would report prescribing highly active antiretroviral therapy and multidrug combinations for treatment of opportunistic infections. Providers with few HIV-infected patients were substantially less likely to report using new therapeutic regimens or new diagnostic tools. We concluded that the preferred regimens of experienced providers are more likely to be consistent with the latest information on treatment for HIV disease than are those of less experienced providers.  (+info)

Early mycological treatment failure in AIDS-associated cryptococcal meningitis. (6/16029)

Cryptococcal meningitis causes significant morbidity and mortality in persons with AIDS. Of 236 AIDS patients treated with amphotericin B plus flucytosine, 29 (12%) died within 2 weeks and 62 (26%) died before 10 weeks. Just 129 (55%) of 236 patients were alive with negative cerebrospinal fluid (CSF) cultures at 10 weeks. Multivariate analyses identified that titer of cryptococcal antigen in CSF, serum albumin level, and CD4 cell count, together with dose of amphotericin B, had the strongest joint association with failure to achieve negative CSF cultures by day 14. Among patients with similar CSF cryptococcal antigen titers, CD4 cell counts, and serum albumin levels, the odds of failure at week 10 for those without negative CSF cultures by day 14 was five times that for those with negative CSF cultures by day 14 (odds ratio, 5.0; 95% confidence interval, 2.2-10.9). Prognosis is dismal for patients with AIDS-related cryptococcal meningitis. Multivariate analyses identified three components that, along with initial treatment, have the strongest joint association with early outcome. Clearly, more effective initial therapy and patient management strategies that address immune function and nutritional status are needed to improve outcomes of this disease.  (+info)

Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. (7/16029)

During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, > 8 micrograms/mL). A macrolide (seven received clarithromycin, one azithromycin) and clofazimine were continued; additional treatment included various combinations of ethambutol, ciprofloxacin, amikacin, and rifabutin. After the detection of a resistant isolate and before receipt of additional antimycobacterials, the median peak MAC colony count in blood was 105 cfu/mL (range, 8-81,500 cfu/mL). After additional antimycobacterials, the median nadir MAC colony count was 5 cfu/mL (range, 0-110 cfu/mL). Five (63%) of eight patients had a > or = 1 log10 decrease, including two who achieved negative blood cultures; all of these responses occurred in patients originally assigned to clarithromycin plus clofazimine. Treatment of clarithromycin-resistant MAC bacteremia that emerges during clarithromycin-based treatment can decrease levels of bacteremia and transiently sterilize blood cultures.  (+info)

A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. (8/16029)

BACKGROUND: Between September 20, 1995 and September 20, 1997, 208 adult patients undergoing renal transplantation were randomized to receive tacrolimus/prednisone (n=106) or tacrolimus/prednisone/mycophenolate mofetil (n=102), with the goal of reducing the incidence of rejection. METHODS: The mean recipient age was 50.7+/-13.7 years. Sixty-three (30.3%) patients were 60 years of age or older at the time of transplantation. The mean donor age was 34.5+/-21.7 years. The mean cold ischemia time was 30.5+/-9.2 hr. The mean follow-up is 15+/-7 months. RESULTS: The overall 1-year actuarial patient survival was 94%; the overall 1-year actuarial graft survival was 87%. When the patient and graft survival data were stratified to recipients under the age of 60 who did not have delayed graft function, the overall 1-year actuarial patient survival was 97%, and the corresponding 1-year actuarial graft survival was 93%. There were no differences between the two groups. The overall incidence of rejection was 36%; in the double-therapy group, it was 44%, whereas in the triple therapy group, it was 27% (P=0.014). The mean serum creatinine was 1.6+/-0.8 mg/dl. A total of 36% of the successfully transplanted patients were taken off prednisone; 32% of the patients were taken off antihypertensive medications. The incidence of delayed graft function was 21%, the incidence of cytomegalovirus was 12.5%, and the initial and final incidences of posttransplant insulin-dependent diabetes mellitus were 7.0% and 2.9%; again, there was no difference between the two groups. CONCLUSIONS: This trial suggests that the combination of tacrolimus, steroids, and mycophenolate mofetil is associated with excellent patient and graft survival and a lower incidence of rejection than the combination of tacrolimus and steroids.  (+info)

At the end of the year, every group demonstrated measurable improvements, with 32 percent of all the patients achieving clinical remission of their disease. However, patients who had received initial combination therapy--either with prednisone (group 3) or with infliximab (group 4)--had significantly less progression of radiographic joint damage than did patients treated with DMARDs only (group 1), or patients assigned to step-up combination therapy (group 2). The number of patients without any progression of radiographic joint damage was also higher in groups 3 and 4 than in groups 1 and 2. Furthermore, RA patients in both initial combination therapy groups experienced earlier functional improvement than did patients in either the DMARD monotherapy or step-up combination therapy group, according to scores of the Dutch version of the Health Assessment Questionnaire. Overall, patients who received initial combination therapy experienced no more side effects than patients in the other two groups ...
The AMBITION trial included a sizable number of patients with CTD-PAH, and within this SSc-PAH, and thus provides an opportunity to explore whether this population responds to initial combination therapy with ambrisentan and tadalafil compared with monotherapy of either agent. Initial combination therapy resulted in a reduction in the risk of clinical failure versus pooled monotherapy of 57% in patients with CTD-PAH and 56% in the subset of patients with SSc-PAH. While inferential statistics are not presented, the 95% CIs around the HR for both CTD-PAH and SSc-PAH were well within the bounds of 0-1. This result is further supported by the secondary endpoints, where we see a greater improvement in plasma NT-proBNP levels and 6MWD on combination therapy compared with monotherapy. The benefit of combination therapy over monotherapy is of similar magnitude to that observed in the whole trial population.. No new safety signals were identified in the CTD-PAH subset. However, some AEs appeared to be ...
Effect of Angiotensin-Converting Enzyme Inhibitor/Calcium Antagonist Combination Therapy on Renal Function in Hypertensive Patients With Chronic Kidney Disease: Chikushi Anti-Hypertension Trial - Benidipine and Perindopril
Effect of Angiotensin-Converting Enzyme Inhibitor/Calcium Antagonist Combination Therapy on Renal Function in Hypertensive Patients With Chronic Kidney Disease: Chikushi Anti-Hypertension Trial - Benidipine and Perindopril
In an MD Anderson-led study presented at the San Antonio Breast Cancer Symposium today, researchers presented new data about a combination drug therapy for women with metastatic breast cancer.. The study, known as Breast Cancer Trials of Oral Everolimus (BOLER0-2 ), found that combining everolimus, with hormonal therapy drug exemestane, resulted in a two-fold increase in progression-free survival for postmenopausal women who received prior endocrine therapy.. Everolimus inhibits the mammalian target of rapamycin (mTOR) protein, a central regulator of tumor cell division and blood vessel growth in breast cancer cells; the mTOR pathway is activated in hormone-resistant breast cancer.. Gabriel Hortobagyi, M.D., professor and chair of MD Andersons Department of Breast Medical Oncology, says the study is based on the concept that recognizes an increased understanding of signaling pathways and the efficacy of using a dual-attack approach to target them.. ...
A post-marketing safety study mandated by the U.S. Food and Drug Administration has shown that a combination drug therapy for the treatment of asthma is safe and effective.
Global combination drugs diagnostic market is expected to witness exponential growth over the coming seven years due to greater efficiency attached to combination diagnosis and accelerated approval of drugs by the regulating authority. In addition, rising geriatric population base, improved diagnostic procedures and growing investments in R&D operations is further expected to drive the growth for combination drugs diagnostic market in near future
Table 6. What to Start: Initial Combination Regimens for Antiretroviral-Naive Pregnant Women. These recommendations are for pregnant women who have never received antiretroviral therapy (ART) previously (i.e., antiretroviral-naive) and who have no evidence of significant resistance to regimen components. See Table 9 for more information on specific drugs and dosing in pregnancy.. Within each drug class and recommendation category, regimens are listed alphabetically, and the order does not indicate a ranking of preference. In addition, The Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission (the Panel) makes no recommendation of one agent or regimen over another within each category (Preferred or Alternative).. It is recommended that women who become pregnant while on a stable ART regimen with viral suppression remain on that same regimen, with the exception of regimens containing didanosine, stavudine, or treatment-dose ritonavir, and (until more data ...
RESULTS: At baseline, there were no differences in demographics, WHO classification, hemodynamics, classification of PAH, or 6MWD among the 3 groups. The 6MWD significantly improved in the combination therapy group compared with the bosentan monotherapy and iloprost monotherapy groups at week 6 (P = .001) and after 3 months (P , .001), respectively. Secondary end points significantly improved in the combination therapy group for mean pulmonary artery pressure, cardiac index, and WHO functional classification after 3 months of treatment and for N-terminal pro-brain natriuretic peptide, Minnesota Living with Heart Failure questionnaire scores, and PaO2 after 6 weeks and 3 months of treatment, compared with the monotherapy groups. ...
Urgency. Despite the great variety of drugs for treatment of CHF rational pharmacotherapy is not always applied in a proper way, especially in using combination therapies. Aim. Evaluating the effects of current combined pathogenetic therapies on clinical manifestations of disease, hemodynamics, morpho-functional parameters of the heart and exercise tolerance in patients with II-IV NYHA FC CHF having complicated the course of IHD. Material and methods. Study was performed on 355 patients aged from 43 to 76 years with II-IV NYHA FC CHF and left ventricular ejection fraction (LV EF) ,45% having complicated the course of IHD. Evaluation of combination therapy efficacy and safety included dynamics of clinical manifestations of disease, hemodynamic parameters, cardiac bioelectric activity and rhythmic performance; dynamics of morpho-functional cardiac parameters; analysis of laboratory data. Results. Pharmacotherapy of II-IV FC CHF having complicated the course of IHD should be a combination ...
ORLANDO, Fla.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced results up to 76-weeks from a Phase 3 study of ONGLYZA™ (saxagliptin) as initial
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
This is the first randomized controlled trial to evaluate the efficacy and safety of the initial combination of an SGLT2 inhibitor and a DPP-4 inhibitor in subjects with type 2 diabetes. Initial combination of empagliflozin/linagliptin led to clinically meaningful reductions from baseline in HbA1c in subjects with type 2 diabetes, with ,50% of subjects reaching HbA1c ,7% (,53 mmol/mol) at week 52. Greater reductions from baseline in HbA1c (of up to 1.93% [21.1 mmol/mol]) were observed with empagliflozin/linagliptin in subjects with baseline HbA1c ≥8.5% (≥69 mmol/mol) compared with those with baseline HbA1c ,8.5% (,69 mmol/mol) who had reductions of up to 0.96% (10.5 mmol/mol). Initial combination of empagliflozin/linagliptin may be an option in patients presenting with marked hyperglycemia, as achieving glycemic targets may be challenging with traditional stepwise treatment escalation, and treatment escalation in clinical practice is often delayed. In a retrospective analysis of ,3,000 ...
Results In total, 975 deaths occurred during 1 year follow-up, culminating to 3247 by 11 years. 1-year risk of death was significantly reduced for all drug combinations, but not for drugs dispensed in isolation. Out to 11 years, only combinations of β-blockers and statins (with or without ACE inhibitors/angiotensin II receptor blockers (ACEi/ARB)) provided significant reductions in risk of all-cause mortality. In men, the greatest reduction in risk was associated with being dispensed β-blockers and statins (HR 0.46, 95% CI 0.36 to 0.58), whereas women benefited most from being dispensed β-blockers, statins and ACEi/ARBs (HR 0.77, 95% CI 0.60 to 0.99).. ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
wp-content/uploads/2014/11/clear-box.png 0 0 admin /wp-content/uploads/2014/11/clear-box.png admin2014-08-13 20:29:332014-12-09 02:37:05The Oupicky lab received a new NIH R01 grant on combination drug/siRNA delivery ...
Several studies have shown that blood pressure can be lowered by the use of drugs that are not traditional antihypertensive drugs. This might be of clinical importance when many risk patients are treated by combination drug therapy in order to prevent cardiovascular disease by way of improving the cardiovascular risk factor profile.
Renal denervation (RDN) represents a device-based hypertension treatment intended to lower sympathetic activity. Only a few years ago, RDN was written off as ineffective after results of the sham-controlled SYMPLICITY HTN-3 trial failed to confirm early trials reports of significant BP reductions in patients resistant to guideline- based combination drug therapy.
The results are shown as imply SEM from three independent experiments. therapies for MM. and models and studied the effects of this combination therapy on guidelines such as cytokine secretion and cell adhesion inside a microenvironment comprising MM cells and BM. Our TVB-3166 results demonstrate the combination of MPT0G413 and BTZ not only induced synergic apoptosis in MM cells, but also downregulated VEGF, TVB-3166 IL-6 secretion to inhibit MM growth inside a MM/BMSC co-culture program. From a translational perspective, these findings could enhance the efficacy of anti-MM treatment potentially. Strategies and Components Components MPT0G413 had been synthesized by Teacher Jing-Ping Liou, as well as the purities had been > 98%. We utilized nonconjugated principal antibodies against HDAC6 (#7612), Caspases-3 (#9661),?8 (#9746), and?9 (#9502), acetyl-histone 3 (#9677), acetyl-histone TVB-3166 4 (#8647), histone 3 (#9715), histone 4 (#2935), acetyl-tubulin (#5335), had been purchased from Cell ...
Scientists are now one step closer to understanding how HIV hides in cells and rears its ugly head once patients stop taking combination drug therapy,
The Kirby Insitute at UNSW has launched a feasibility study to examine whether HIV negative people can take combination drug therapy to reduce their risk of acquiring the virus.. ...
In patients with pulmonary arterial hypertension (PAH) combination therapy with intravenous PG12 may lead to greater disease burden, finds study.
The relative effects of FLOT were demonstrable in all subgroups, and was pronounced numerically in patients with esophageal tumors.
In my opinion immunosuppressant and anti-CD20 therapy (rituximab) is the preferred option for these patients. The actual therapy recommended will depend on the situation but could include periodic steroids, azathioprine, mycophenolate, cyclophosphamide or rituximab. A newer therapy for MS called teriflunimide (Aubagio) could be strongly considered as well because of its mechanism of action. Many patients end up on combination therapies that may include Copaxone plus one of the agents previously mentioned ...
Five years later, she saw the same doctor again after contracting a minor ear infection. During the course of her consultation the doctor (despite having been asked not to) told her that her previous CD4 count had been 26. As the readers may imagine, my friend was extremely upset and frightened at hearing this news. The doctor again tried to persuade her to start the ARVs, despite the fact that she had remained in good health for the more than five years since that count of 26 had been carried out. Instead she went to see a counselor who reminded her that she was as healthy the day after having been told her CD4 count had been 26 (five years previously), as she was the day before hearing the news. She declined the offer to go on combination therapy and 18 months later, remains in good health - nearly seven years after her blood counts indicated she had AIDS (according to the CDC definition) and more than 20 years after becoming infected ...
The filing by GSK of a regulatory submission closed triple combination therapy FF/UMEC/VI 100/62.5/25 mcg for patients with COPD.
A targeted three-drug combination therapy resulted in median overall survival of nine months for patients with advanced bowel cancer.
A pain reliever many people consider harmless can cause liver failure and even death if taken in excess. To reduce the number ... Food and Drug Administration (FDA)
In principle, modern combination therapies are very effective at keeping AIDS causative agents in check. The treatment usually leads to a situation in which there is no longer any evidence of Human-Immunodeficiency Viruses (HIV) in the body. In this way, the drugs can also reduce the disease transmission rate to just one tenth. So why do new infections occur despite treatment?. Sperm containing a cocktail of viruses. The answer, according to findings recently published(*) by the Swiss researcher Sara Gianella Weibel and her American colleagues, is that other viruses also play a role. Working at the University of California in San Diego, the SNSF-funded scientist studied the semen of 114 HIV-infected men undergoing treatment who have sex with men. She found that the seminal fluid of 11 of the men contained a considerable quantity of HI viruses, even though the viral load of the blood of all of the men was very low. In eight of these 11 cases, Gianella Weibel also found evidence of various forms ...
I am afraid that the opinion remains that the paper is not a strong candidate for publication… Rejection. Failure. Almost everyone will experience a mixture of these during ones lifetime. But for a scientist, this has become the norm of our existence: failed scientific experiments, rejected grants, and scathing remarks from manuscript reviewers. The one thing that is certain in academia, is that you will have many failures; what is not as certain is ones response to such adversity. I hope this piece can give practical advice on how to overcome failure and even potentially change our perspective on what failure is, with an emphasis on what steps young scientists, such as graduate students who are just beginning their journey, can take. Turning your negative response into a therapeutic one Our typical response to rejection in science (and most other endeavors) is an initial combination of anger and/or disappointment, that can progress to self-pity, blaming the system, and depre ...
Buy Balkatrin Online! Balkatrin treats several types of bacterial infections. Drink plenty of fluids with this medication. Balkatrin is an effective combination antibiotic; however, it may not be suitable for those with kidney or liver disease or folate deficiency.
We found a large average difference in HSBP in favor of initial use of combination therapy compared with initial monotherapy across the first 8 months of the study (phases 1 and 2); there was no discernible subset of patients in whom this difference was not observed. It was largely due to the superiority of combination therapy in the first 16 weeks (phase 1), by margins of almost 8 and 10 mm Hg, respectively, for home and clinic systolic BP. Although combination therapy is expected to show superior efficacy and is recommended for stage 2 hypertension by some guidelines, this has not yet become the norm in routine practice. Consequently, we incorporated a number of planned measurements in the study design that we believed, if positive, would help to change practice.. The first of the additional measurements was the co-primary end point of HSBP at 32 weeks, the prespecified time point for evaluation of the never‐catch‐up hypothesis that initial less intense BP control results in subsequently ...
While erythromycin (EM) has been shown to play an anti-inflammatory role in COPD, it is unclear whether a combination of EM and corticosteroid would further reduce inflammatory effects. Here, we determined the molecular mechanisms by which combination therapy may repress inflammatory gene expression in monocytes. We demonstrated that combination treatment inhibited release of IL-8 in PBMCs of COPD patients and U937 exposed to CSE. ...
This is really the first step in demonstrating that two-drug regimens can be as effective as three-drug regimens, says Kimberly Smith, M.D., M.P.H.
Benicar HCT is a combination drug often used in the treatment of high blood pressure in adults. This eMedTV resource takes an in-depth look at this drug, with information on possible side effects, dosing guidelines, and more.
Expert Rev Respir Med. ( 2020 Feb 13. doi: 10.1080/17476348.2020.1730180. [Epub ahead of print] Assessment of efficacy of oseltamivir-azithromycin combination therapy in prevention of influenza-a (H1N1) infection complications and rapidity of symptom relief. Ishaqui AA
Dr. Cox responded: Within reason. Varying the dose time by 4 hours is not bad. Its when you skip days that you get into trouble. All the best.
Counselors at Kalamazoo Therapy Group help create positive long-lasting changes for yourself, your relationships and your mental health.
Mindol Plus in Punjabi - ਵਰਤੋਂ, ਖੁਰਾਕ, ਬੁਰੇ ਪ੍ਰਭਾਵ, ਲਾਭ, ਪਰਸਪਰ ਪ੍ਰਭਾਵ ਅਤੇ ਚੇਤਾਵਨੀ ਦੇਖੋ - Mindol Plus varton, khurak, bure prabhav, laabh, paraspar prabhav ate chetavni
Celor Plus in Punjabi - ਵਰਤੋਂ, ਖੁਰਾਕ, ਬੁਰੇ ਪ੍ਰਭਾਵ, ਲਾਭ, ਪਰਸਪਰ ਪ੍ਰਭਾਵ ਅਤੇ ਚੇਤਾਵਨੀ ਦੇਖੋ - Celor Plus varton, khurak, bure prabhav, laabh, paraspar prabhav ate chetavni
Therapy with the initial combination of sitagliptin and metformin was assessed for efficacy and tolerability in patients with type 2 diabetes who had inadequate glycemic control with diet and exercise. In this study, all active treatments produced clinically meaningful reductions in A1C, FPG, and 2-h PPG compared with placebo, and the coadministration groups provided greater reductions relative to the individual monotherapies (compared at the same metformin dose). After reaching the nadir, the changes in A1C and FPG were relatively stable over 24 weeks in all active treatment groups. Greater proportions of patients achieved A1C targets with all active treatments relative to placebo, with the coadministration of sitagliptin and high-dose metformin getting about two-thirds of patients to the A1C goal of ,7%.. As with other antihyperglycemic agents (24), including sitagliptin (9,11), patients with more severe baseline hyperglycemia (i.e., A1C ≥9%) had the largest reductions with coadministration ...
BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination therapy with 10 mg of ambrisentan plus 40 mg of tadalafil (combination-therapy group), 10 mg of ambrisentan plus placebo (ambrisentan-monotherapy group), or 40 mg of tadalafil plus placebo (tadalafil-monotherapy group), all administered once daily. The primary end point in a time-to-event analysis was the first event of clinical failure, which was defined as the first occurrence of a composite of death, hospitalization for worsening pulmonary arterial hypertension, disease progression, or unsatisfactory long-term clinical response.
Recent reviews and meta-analyses of RCTs, including the IMPROVE-IT study, showed that ezetimibe was likely associated with a reduction of the risk of myocardial infarction and stroke, without affecting the risk of overall or cardiovascular mortality or newly-developed cancer [21,22]. However, published reviews reported marginal cardiovascular benefits of ezetimibe when ezetimibe was added to statins for reducing nonfatal myocardial infarction and stroke (17 fewer myocardial infarctions and six fewer strokes per 1,000 persons treated over 6 years) [21,22,23,24]. This uncertainty is reflected in the absence of a consensus regarding ezetimibe in international guidelines. The 2013 treatment guidelines of the American Heart Association/American College of Cardiology (AHA/ACC) focused on statin monotherapy and did not suggest considering second-line drugs, including ezetimibe, as a treatment option based on a lack of strong evidence [4]. However, European and Korean guidelines for the management of ...
Researchers at the National Institutes of Health have discoveredthat a combination of protease inhibitors and other anti-HIV drugsused to treat people with AIDS can prevent or delay the progression ofcytomegalovirus (CMV) retinitis, a potentially blinding eyecomplication of AIDS. A letter detailing these findings is publishedin the May 21, 1997 issue of the Journal of the American MedicalAssociation(JAMA).
THURSDAY, Feb. 26, 2015 (HealthDay News) - The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, including the kidneys.. Avycaz contains the previously approved antibiotic ceftazidime, and the newer antibacterial drug avibactam, the agency said in a news release. Approved to help combat antibacterial resistance, Avycaz is sanctioned for people who have limited or no other treatment options, the FDA said.. The most common side effects identified during clinical testing included vomiting, nausea, constipation, and anxiety. Users with poor kidney function had more serious adverse reactions, including decreased effectiveness and seizures. And users allergic to penicillin may be at greater risk of serious skin reactions and anaphylaxis, the FDA warned.. The FDA is committed to making therapies available to treat patients with unmet medical need, ...
Sterling8 and colleagues in a recent non-inferiority trial published in the New England Journal of Medicine compared the efficacy of a 3-month therapy containing the combination of INH (900mg) plus rifapentine (900 mg), given once weekly under supervision, to the efficacy of a 9-month therapy with daily, self-administered INH (300mg). The main question was whether the efficacy and effectiveness of the combination therapy would be at least as good as INH alone. During the 33-month follow up in a total of 7731 subjects, the effectiveness analysis counted only 7 cases of tuberculosis in the combination-therapy group compared to 15 cases in the INH-only group (HR=0.38 (95% CI, 0.15 to 0.99)). Better adherence and fewer episodes of hepatotoxicity were observed in the shorter, supervised combination therapy than the INH alone therapy. Hypersensitivity however was more commonly associated with the combination of INH plus rifapentine. This trial suggests that the combination of rifapentin and INH could ...
Results of a new 12-week study combining iloprost and bosentan showed improvements in patients with pulmonary arterial hypertension (PAH). University of Michigan Medical Center researchers followed 65 PAH patients being treated with the endothelian receptor antagonist bosentan. Thirty-two patients began taking inhaled iloprost in addition to bosentan; 33 received bosentan plus placebo. At the end of 12 weeks, the bosentan-iloprost group could walk 98 feet farther in their 6-minute walk test. Eleven of the 32 in the combination-therapy group showed improvement, and none of them showed signs of clinical deterioration. PAH is characterized by a progressive narrowing of the blood vessels in the lungs and can be fatal. Symptoms, which only get worse over time, include shortness of breath, fatigue, weakness, dizziness, and fainting. The report can be found in the December 2006 issue of the American Journal of Respiratory and Critical Care Medicine. Ms. Farley is a freelance medical writer based in ...
Mayers latest research includes trials studying the effect of combination drug therapies in metastatic estrogen receptor-positive (ER+), endocrine therapy-refractory breast cancer and metastatic triple-negative breast cancer (TNBC) patients. The benefits could include a highly active therapy (without traditional chemotherapy) that increases overall survival, and possibly even cure rates in metastatic disease.. One of the drugs contains an anti-PD-L1 antibody known to work in 10-20 percent of patients; the second is a MEK inhibitor. Mayer believes the antibody will help unmask the tumor to the immune system and make the immunotherapy drug work better in a greater percentage of patients. A unifying dogma is that estrogen-positive cancers are immunotherapy cold, she said. Were hoping to prime the cancer to be more responsive.. Overall, the trials could help develop both predictive biomarkers of response and early (on-treatment) biomarkers of response, and with additional laboratory ...
Salt sensitive hypertension is known to be a contributing factor for the progression of kidney disease. This study was undertaken to investigate the role of excessive dietary salt on renal function and to evaluate the effect of valsartan and amlodipin given as a combination therapy on blood pressure and parameters specific to the renal function in salt loaded SHR rats. 48 male SHR rats at age of 20 weeks and body weight ranging between 270-350 g were used. SHR rats were divided into 3 groups: control group of rats -SHRC (n = 16) given tab water ad libitum and two salt treated groups in which tab water was replaced with a solution of NaCl (1%) from age of 8 weeks given ad libitum: SHRVAL+AMLO group (n = 16) where investigated drugs were administered at a dose of 10 mg/kg/ b.w. (valsartan) and 5 mg/kg/ b.w. (amlodipin) by gavage and SHR NaCl group (n = 16) that received saline in the same volume and the same time intervals as the SHRVAL+AMLO group. For a period of 12 weeks we have investigated the ...
Salt sensitive hypertension is known to be a contributing factor for the progression of kidney disease. This study was undertaken to investigate the role of excessive dietary salt on renal function and to evaluate the effect of valsartan and amlodipin given as a combination therapy on blood pressure and parameters specific to the renal function in salt loaded SHR rats. 48 male SHR rats at age of 20 weeks and body weight ranging between 270-350 g were used. SHR rats were divided into 3 groups: control group of rats -SHRC (n = 16) given tab water ad libitum and two salt treated groups in which tab water was replaced with a solution of NaCl (1%) from age of 8 weeks given ad libitum: SHRVAL+AMLO group (n = 16) where investigated drugs were administered at a dose of 10 mg/kg/ b.w. (valsartan) and 5 mg/kg/ b.w. (amlodipin) by gavage and SHR NaCl group (n = 16) that received saline in the same volume and the same time intervals as the SHRVAL+AMLO group. For a period of 12 weeks we have investigated the ...
In this study, non-inferiority of ETN monotherapy compared with the ongoing combination of ETN and MTX, after 6 months of combination therapy in MTX-IRs, was not demonstrated. From 6 to 12 months, DAS28 was stable in patients on ETN+MTX and increased slightly in patients on ETN monotherapy. However, the mean difference between treatment groups was 0.45; thus, in some patients, the difference may not be clinically meaningful, whereas in others, their change in DAS28 after stopping MTX was clinically meaningful. One can potentially determine which patients may benefit from continuing MTX for the next 6 months vs stopping MTX. The subset of patients with LDA at 6 months achieved a similar DAS28 and EULAR response at 12 months whether on monotherapy or combination therapy. Conversely, patients with MHDA at 6 months performed better on combination therapy.. CAMEO, unlike other studies, focused on the disease state required to sustain ETN monotherapy regardless of the disease state at randomisation, ...
The majority of patients with pulmonary arterial hypertension, except for a few special circumstances, will begin treatment on combination therapy, instead of monotherapy, because combination therapy has been shown in trials to ahve better outcomes, explained Simon Gibbs, MD, Reader in Pulmonary Hypertension at the National Heart and Lung Institute, Imperial College London.
Complex diseases, such as Type 2 Diabetes, are generally caused by multiple factors, which hamper effective drug discovery. To combat these diseases, combination regimens or combination drugs provide an alternative way, and are becoming the standard of treatment for complex diseases. However, most of existing combination drugs are developed based on clinical experience or test-and-trial strategy, which are not only time consuming but also expensive. In this paper, we presented a novel network-based systems biology approach to identify effective drug combinations by exploiting high throughput data. We assumed that a subnetwork or pathway will be affected in the networked cellular system after a drug is administrated. Therefore, the affected subnetwork can be used to assess the drugs overall effect, and thereby help to identify effective drug combinations by comparing the subnetworks affected by individual drugs with that by the combination drug. In this work, we first constructed a molecular interaction
Combination therapy has gained momentum in oncology in recent years, with various studies demonstrating higher response rates with combinations of drugs compared to monotherapies,[2][3] and the FDA recently approving therapeutic combination regimens that demonstrated superior safety and efficacy to monotherapies.[4] In a recent study about solid cancers, Martin Nowak, Bert Vogelstein, and colleagues showed that in most clinical cases, combination therapies are needed to avoid the evolution of resistance to targeted drugs. Furthermore, they find that the simultaneous administration of multiple targeted drugs minimizes the chance of relapse when no single mutation confers cross-resistance to both drugs.[1]. Various systems biology methods must be used to discover combination therapies to overcome drug resistance in select cancer types.[5][6] Recent precision medicine approaches have focused on targeting multiple biomarkers found in individual tumors by using combinations of drugs.[7] However, with ...
Researchers found that a combination of vaccine and chemotherapy sessions may help boost both progression-free survival and overall survival rates for patients suffering from glioblastoma, a malignant tumour affecting the brain or spine.
Actinium Pharmaceuticals says that exposing venetoclax-resistant AML cells to a CD33-targeted antibody radionuclide conjugate may resensitize cells to the drug and improve patient outcomes.
Wittkop L., Günthard HF, de Wolf F., Dunn DT, Cozzi-Lepri A, De Luca A., Kucherer C., Obel N., von Wyl V., Masquelier B. et al.. 2011. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 11:363-71. ...
Background Individuals with metastatic sarcoma who all improvement on vascular endothelial development aspect receptor inhibitors (VEGFRi) have got limited treatment plans. these sufferers was 3.1 months which range from 0.5 to 7.2 a few months with one individual remaining on combination therapy. Bottom line In this intensely pre-treated, advanced sarcoma people, the addition of mTOR inhibition to VEGFRi structured therapy led to a clinical advantage for the subset of sufferers. Prospective research will be had a need to confirm these results. Launch Soft tissues and bone tissue sarcomas take into account significantly less than 1% of most adult malignancies [1]. While improvements in therapy have already been made, MK-0679 median success after advancement of MK-0679 faraway metastases is certainly 11 to 15 a few months [2]. Multiagent cytotoxic regimens possess demonstrated response prices which range from 16 to 46% within this people [3,4], nevertheless tolerability remains a problem. ...
Physicians need to be aware of the risk factors for MDR bacterial infections, Dr. Pop-Vicas said, and should be judicious in prescribing antibiotics. Treating infections caused by MDR bacteria is a therapeutic challenge, Dr. Pop-Vicas said, because for severe infections, physicians may need to administer medicine before the bacterial culprit--and its potential resistance to antibiotics--is known. In such cases, combination antibiotic therapy (using more than one drug at a time) may be preferable to monotherapy (using one drug) because physicians want to maximize the chance that the organism is sensitive to at least one of them, Dr. Pop-Vicas said. Starting to treat an infection with inadequate therapy is associated with a worse outcome than using adequate therapy from the start, she added. Once the bacteriums drug resistance is known, the therapy can be adjusted accordingly ...
The Agilent 1290 Infinity II High Dynamic Range Diode Array Detection Impurity Analyzer Solution combines the signals from two diode array detectors with different path length Max-Light cartridge cells to increase the linear dynamic UV-range. This solution can be used to detect and quantify main and trace compounds in a single run without exceeding the linear UV-range.
But still, there is some concern. For several years, doctors have been warning of the emergence of drug-resistant bacteria. The problem is attributed to overuse or misuse of antibiotics. An experimental French drug called Synercid could prove to be an effective new antibiotic against the resistant bug. In the meantime, many hospitals have restricted use of their most potent antibiotics, isolated their sickest patients and instructed staff members to wash their hands often. Its of interest and concern because it represents an instance in which an effective antibiotic has become ineffective in treating a common organism, Adel said. People at greatest risk to the staph bacteria are those with weakened immune systems, including newborn babies, the elderly, and cancer and AIDS patients. Even though the New York patient was at high risk and he never got a chance to get combination antibiotic therapy, health officials are taking no chances at further infections. Hospitals will continue to follow ...
To alleviate pain, especially headaches, scientists are relying more on combined analgesics rather than sticking to mono therapy.
Glaucoma Therapeutics Market: Scope and Methodology The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and…
2015 FC 959 - The Health Minister denied data protection for Cysview after finding it was not an innovative drug, and the FC indicated the scope of innovative drug does not extend to combinations of the enumerated variations of previously approved medicinal ingredients in the Regulations (salt, ester, enantiomer, solvate or polymorph ...
This study has shown that extensive changes in drug regimens were made during these patients hospital stays. This is not surprising because hospitalised patients are often seriously ill or are experiencing deteriorations in chronic diseases. It is noteworthy that three-quarters of the patients were discharged with at least three changes to their drug regimens relative to their drug regimens at admission. The addition of new drugs markedly exceeded the number of drug discontinuations. Other studies have also reported that drug regimens are frequently changed during hospital stays.3 ,4 ,7 ,10 However, Himmel et al3 did not state whether the changes were continued until discharge from hospital, and in a one-day survey, Karapinar et al10 did not report whether these changes were maintained after discharge. Grimmsmann et al7 compared prescriptions during a 3-month period before admission and after discharge but did not relate the changes to the medication list at discharge. In comparison, we ...
Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: Its role in preventing HIV infection in infants
The combination drug ledipasvir/sofosbuvir may offer a hint of added benefit in sustained virologic response (SVR) for some patients with genotype 1 hepatitis C infection (HCV) compared to other therapies, reports the German Institute for Quality and Efficiency in Health Care (IQWiG).
M.D., Ph.D., evaluated the effects of combining PS-targeting, anti-PD-1 and radiation therapies in the mouse B16 melanoma model. Study data showed that PS-targeting antibodies synergize with both anti-PD-1 and radiation therapy to improve anti-cancer activity. PS-targeting treatment in combination with radiation, as well as triple combination of PS-targeting treatment, anti-PD-1 and radiation, led to a reduction in tumor burden. Median survival for the triple combination treatment still had not been reached at the end of the 80-day observation period with other arms in the study showing median survival that ranged from 24-70 days. Researchers also evaluated the impact of the PS-targeting and radiation combination treatment on the level and type of immune activity. These results demonstrated that the combination led to a change in the tumor microenvironment, shifting it from immunosuppressive in which tumors are protected to immune active in which tumors are more susceptible to treatment. ...
To confirm the efficacy and safety of PRO143966 with Ro50-8231 as primary therapy in patients with Met-positive advanced, metastatic or postoperatively
Question - Behavior worsened after decrease in Vyvanase dosage, also taking Seroquel. Should I continue with the same dosage?. Ask a Doctor about uses, dosages and side-effects of Vyvanse, Ask a Psychiatrist, Child
Aspirin - a combination drug. Acetylsalicylic acid has anti-pain, analgesic, high doses anti-inflammatory effects. Has antiplatelet (prevents clot formation)
The first of a two-part series that talks about the side effects of chemotherapy, and what measures doctors take to help patients cope with them.
Aceclofenac 100mg and Tizanidine 2mg combination drug is used for treating inflammation and pain. Each tablet costs $1.25. Order more than 30 tablets at IDMRx and save up to $27.36
Shop Blemish Relief Combination Therapy 90 Day Regimen by Perricone MD at MECCA. A trio of targeted skincare products that fight acne-causing bacteria.
Bhava is a Sanskrit word that refers to our emotional and mental state of mind. It is both a descriptive and action-oriented word that means being and becoming. Bhava also refers to the act of setting or receiving an attitude of peace, vitality and wellness.. Bhava most poignantly expresses what we do and provide to every person who walks through our door. At Bhava Therapy Group, we fully respect and value the unique being of each person who turns to us for help. We are committed to doing our very best to facilitate and guide each person along their path of becoming their most healthy and vital self.. ...
This study will evaluate the antiviral efficacy of therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) and the safety and tolerability of
In this weeks video, Dr. Durie discusses how to tell if you are refractory to the drug Revlimid® and what other combination therapies could be available as an alternative. BOTTOM LINE: Determine with your doctor if you are refractory to Revlimid®. If so, discuss treatment options carefully.
Storage needs will be met by a hierarchy with flash-caches and SATA taking a predominant role as the most cost effective combination for most
Which one do you like best? I personally find BigBrother stupid...who wants to watch people in a house all day? Plus, I dont like how it is like a talk-show at the same time. But I do like Survivor a lot ------------------ - The Web Developer Headquarters
We offer online therapy to clients who reside all over Florida. Speak with a licensed therapist from the comfort of your home or during your lunch break!
The two drugs had similar potencies; combination therapy was not significantly better than monotherapy.. ... Drug(s) Neuropathic POTS Alpha-1 adrenergic receptor agonist Constrict the peripheral blood vessels aiding venous return. ... POTS treatment involves using multiple methods in combination to counteract cardiovascular dysfunction, address symptoms, and ... Food and Drug Administration to treat POTS, but a variety are used off-label.[12] Their efficacy has not yet been examined in ...
A targeted therapy drug, Kadcyla, was approved in February 2013. This antibody-drug conjugate targets only cancerous cells. It ... Scheduling of drug treatments and combination treatment can have substantial impact on treatment efficacy. Nanomedicine is ... In most cases, however, the combination of radiotherapy and hormonal therapy is not enough to maintain disease control, and ... Chemotherapy is one of the most important components of therapy for metastatic breast cancer. Therapy of choice is based on ...
Lange, Joep (1995). "Combination Antiretroviral Therapy". Drugs. 49 (Supplement 1): 32-37. doi:10.2165/00003495-199500491-00008 ... During the mid-1990s, Lange began advocating for the use of combination therapy in the management of HIV/AIDS. He argued that ... He found that a baby's chance of contracting HIV falls to less than 1% if they receive anti-retroviral drugs while being nursed ... He was also a founding editor of the medical journal, Antiviral Therapy. In 2006 he became Professor of Medicine at the ...
Some of the drugs can be used in combination.[7] A common triple therapy for rheumatoid arthritis is methotrexate, ... Combinations of DMARDs are often used together, because each drug in the combination can be used in smaller dosages than if it ... "Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid ... Disease-modifying antirheumatic drugs (DMARDs) is a category of otherwise unrelated drugs defined by their use in rheumatoid ...
A new combination drug therapy (sulfonamide, ceftriaxone, and amikacin) has also shown promise. The prognosis of nocardiosis is ... In patients who do not respond to sulfonamide treatment, other drugs, such as ampicillin, erythromycin, or minocycline, may be ... even with appropriate therapy. It is one of several conditions that have been called "the great imitator". Cutaneous ... cure rate with appropriate therapy. The cure rate falls to 63% with those infected with disseminated nocardiosis, with only ...
Treatment of infection often involves a combination of antifungal drug therapy and surgical excision. Ochroconis gallopava was ... Also, antifungal drug therapy and surgical excision can be used to treat the infection separately or together. O. gallopava ... These drugs and surgical methods are the most effective when the fungus is yet disseminated into the brain. Survival rate of ... However, both antifungal drugs and surgical excision do not guarantee the perfect cure; there are some reported cases of ...
There is also current experimental research on non drug related therapies. Oxymatrine, for example, is a root extract found in ... the FDA approved simeprevir for use in combination with peginterferon-alfa and ribavirin.[78] Simeprevir has been approved in ... "Food and Drug Administration. Nov 22, 2013.. *^ "Medivir: Simeprevir has been approved in Japan for the treatment of genotype 1 ... It has been reported to be the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection ...
... has become an important drug in the combination therapy for malaria treatment in Africa. It is often used in ... combination with artensunate as a by mouth artemisinin-based combination therapy (ACT) for uncomplicated P. falciparum malaria ... August 2001). "Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum ... Expert Opinion on Drug Safety. 6 (6): 631-5. doi:10.1517/14740338.6.6.631. PMID 17967151. S2CID 29173076. Profiles of Drug ...
"U.S. Moves to Expand Array of Drug Therapies Deployed Against Coronavirus". The Wall Street Journal. March 19, 2020. Braun, ... Commissioner, Office of the (November 23, 2020). "Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment ... Research, Center for Drug Evaluation and (June 26, 2020). "FDA cautions against use of hydroxychloroquine or chloroquine for ... This contrasted with the position of the NIH, which stated the drug was "very unlikely to be beneficial to hospitalized ...
Stencel, Christine (20 July 2004). "Up to $500 Million Needed Annually for Subsidy to Make Artemisinin Combination Therapy the ... 225 million partnership to bring effective malaria drugs to all who need them". The Global Fund to Fight AIDS, Tuberculosis and ... artemisinin-based combination therapy, and the contribution of modeling to policy choices" (PDF). Am. J. Trop. Med. Hyg. 71 ( ... artemisinin-based combination therapies, ACTs). It works primarily through the commercial private sector, in addition to the ...
"Combination Therapy and Drug Interactions". In Levy RH, Mattson RH, Meldrum BS, Perucca E (eds.). Antiepileptic drugs (5th ed ... Center for Drug Evaluation and Research. "Drug Interactions & Labeling - Drug Development and Drug Interactions: Table of ... "Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers". Park JY, Kim KA, Kim SL (November 2003 ... Flockhart DA (2007). "Drug Interactions: Cytochrome P450 Drug Interaction Table". Indiana University School of Medicine. ...
These are all antimalarial drugs and are still used in artemisinin-combination therapy. After Saigon fell on 30 April 1975, ... As the first line strategy, the troops were given synthetic drugs. Drug combinations using pyrimethamine and dapsone, ... The US Food and Drug Administration approved the drug in 2009. China portal Yunnan Baiyao Drug discovery Antimalarial ... mechanisms of action and combination therapy of artemisinin". Expert Review of Anti-infective Therapy. 7 (8): 999-1013. doi: ...
It is used as an injection therapy, often in combination with other drugs. It is used in combination with 5-fluorouracil as a ... Retrieved 30 September 2018. "Sutent Approval History". Retrieved 30 September 2018.. ... N-indol-1-amide compound is a possible anti-tumor drug in combination with other anticancer treatment and has an IC50 value of ... In vitro protein binding is 99,5% for both drugs. The drugs are mainly metabolized in the liver by oxidative metabolism of ...
Fexofenadine, an antihistamine drug used in treatment of allergies, has shown promise in a combination therapy in some studies. ... Raithel M, Winterkamp S, Weidenhiller M, Müller S, Hahn EG (July 2007). "Combination therapy using fexofenadine, disodium ... Helminthic therapy using the whipworm Trichuris suis has been shown in a randomized control trial from Iowa to show benefit in ... "Molecular Therapy. 18 (7): 1365-72. doi:10.1038/mt.2010.54. PMC 2911249. PMID 20389289.. ...
"Combination Therapy for Acne Scarring: Personal Experience and Clinical Suggestions". Journal of Drugs in Dermatology (Review ... Combination therapy[edit]. Combination therapy-using medications of different classes together, each with a different mechanism ... "Drug Trials Snapshots: Aklief". U.S. Food and Drug Administration (FDA). 11 October 2019. Archived from the original on 19 ... Aslam I, Fleischer A, Feldman S (March 2015). "Emerging drugs for the treatment of acne". Expert Opinion on Emerging Drugs. 20 ...
"Combination Therapy Targets Pancreatic Cancer Stem Cells". NCI Cancer Bulletin. 6 (8). 21 April 2009. Archived from the ... "Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer" at "Drug Dictionary: CS-1008". National ... The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or ... "International Nonproprietary Names for Pharmaceutical Substances (INN): List 60" (PDF). WHO Drug Information. " ...
Beginning in the 1990s, piperaquine was tested and adopted as a partner drug for artemisinin combination therapy. Guidelines ... This combination is one of several artemisinin combination therapies recommended by the World Health Organization for treatment ... and is instead used as a partner drug for artemisinin combination therapy. Piperaquine kills parasites by disrupting the ... CS1 maint: discouraged parameter (link) Eastman RT, Fidock DA (2009). "Artemisinin-based combination therapies: a vital tool in ...
1981 - World Health Organization (WHO) recommends a new combination drug treatment for leprosy, MDT (Multi Drug Therapy). ... 1960s - Leprologists work to discover new drugs that are effective against leprosy as many people are discovered to have ... 1980 - Vincent Barry and his team win the 1980 UNESCO Science Prize for their discovery of anti-leprosy drug clofazimine, ... WHO Multidrug therapy (MDT)". WHO. Retrieved 2019-05-22. "StackPath". "StackPath". www.leprosymission. ...
Prednisone, the last drug in the CHOP combination therapy is a corticosteroid that acts as an immunosuppressant.[citation ... The most important part of this combination therapy, however, is the synergism between the drugs. While researchers are not ... Although this drug still cannot strictly target cancer cells, cancer cells have a higher average turnover of microtubules ... This also allows for patients to receive lower and fewer doses of the drug and experience fewer side effects. Newer cases are ...
Today, a four-drug combination therapy exists, but it takes six months or more to be effective. This requires a degree of ... Currently, there are four first-line tuberculosis drugs given as a combination therapy over an extended period of time. Some ... When infections become resistant to first-line drugs, more expensive therapies must be used to treat them. Lengthier treatment ... Combination therapies are essential for treating active tuberculosis infections. ...
... is a combination drug involving a gene therapy agent and a prodrug. It is a candidate drug to treat brain ... The combination drug was designed to be used after a brain tumor is removed surgically; Toca 511 is intended to be injected ... By July 2017 the EMA had granted the combination priority review status, and the FDA had granted it Breakthrough Therapy ... The combination is under development by Tocagen and as of July 2017 phase 2/3 trials were underway for recurrent astrocytoma ...
Among these are the water-soluble coenzyme Q10 formulation, the prescription drug Tanakan, and combination antioxidant therapy ... Sep 2010). "A combination antioxidant therapy prevents age-related hearing loss in C57BL/6 mice". Otolaryngology-Head and Neck ... Antioxidant therapy - age-related hearing loss was reduced in animal models with a combination agent comprising six antioxidant ... They may include: Ototoxic drugs: Ingestion of ototoxic drugs like aspirin may hasten the process of presbycusis. vascular ...
Hormonal therapy may improve responses to antimyoclonic drugs in some people. Some studies have shown that doses of 5- ... Sodium valproate is an alternative therapy for myoclonus and can be used either alone or in combination with clonazepam. Some ... Some drugs being studied in different combinations include clonazepam, sodium valproate, piracetam, and primidone. ... and similar drugs, and is possibly a sign of high and/or rapidly increasing serum levels of these drugs. Myoclonic jerks caused ...
Author Steers, William D. Viability and safety of combination drug therapies for erectile dysfunction. Author Steers, William D ... Steers was a member of the U.S. Food and Drug Administration's Reproductive Medicine Advisory Panel, and chaired the National ...
The many drug therapies under study for neurofibromas are in various stages of research; more time will be required to ... The combination of erlotinib with sirolimus was studied to treat low-grade gliomas. Early research has shown potential for ... Tipifarnib (also known as drug R115777) inhibits the activation of RAS. This drug is a Farnesyltransferase inhibitor which ... Therapy, and Patient Management" (PDF). Denver: Mountain States Genetic Foundation. Klesse, Laura (2010). "Current Therapies ...
Treatment trials test experimental drugs, new combinations of drugs, or new approaches to surgery or radiation therapy. ... "Investigational New Drug (IND) Application - Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug ... what the drug does to the body) and pharmacokinetics (what the body does to the drugs).[36] For a test drug, the trial ... Some drug trials require patients to have unusual combinations of disease characteristics. It is a challenge to find the ...
Combination of several (typically three or four) antiretroviral drugs is known as highly active anti-retroviral therapy (HAART ... Gene therapy[edit]. Gammaretroviral and lentiviral vectors for gene therapy have been developed that mediate stable genetic ... However these drugs can quickly become ineffective due to the fact that the gene sequences that code for the protease and the ... Industrial drugs that are designed as protease and reverse-transcriptase inhibitors are made such that they target specific ...
However, resistance to HOMAPAK emerged, and drug recommendations by the WHO changed to artemisinin combination therapy (ACT). ... HIV treatment in Uganda has centered on human antiretroviral therapy through cross-training and increasing the scope of health ... Bunnell, Rebecca (2006). "Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention ... and preventative therapy for pregnant women. The disease burden of malaria, however, remains high and is further strengthened ...
This is the first approved therapy for advanced BCC. 2012: Perjeta (pertuzumab): For use in combination with Herceptin ( ... Protropin, a drug used to treat dwarfism, was Genentech's first marketed drug and its $2 billion in sales has contributed ... Gazyva is the first drug with breakthrough therapy designation to receive FDA approval. 2014: Esbriet (pirfenidone): An anti- ... "UCSF enters drug discovery agreement with Genentech". FierceBiotech. February 19, 2010. Archived from the original on April 4, ...

No data available that match "drug therapy combination"

  • This study will allow for therapy of all patients with chronic hepatitis C with the combination of alpha interferon and ribavirin and will allow for therapy of patients with resistant forms of chronic hepatitis C with ribavirin alone and will address whether monotherapy with ribavirin can sustain these improvements and whether the biochemical improvements reflect amelioration of the underlying liver disease as judged histologically. (
  • Therapy with the low to moderate doses of the two drugs in a combination agent more effectively lowers blood pressure than monotherapy with a higher dosage of either drug alone-and with fewer side effects. (
  • An increasing number of women may require combination antiretroviral therapy for their own disease because they may be resistant to ZDV, may have high viral loads, or may have previously transmitted HIV to an infant while on ZDV monotherapy. (
  • The results showed that while combination therapy was no better than monotherapy, patients who took combination therapy had a reduction in new lesions on MRI scan. (
  • This is the first NIH-sponsored, multi-center, comparative trial evaluating the benefits of both combination therapy and monotherapy in MS," said lead author Fred Lublin, MD, Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at The Mount Sinai Medical Center . (
  • The study is the first to show that a combination trial is feasible in MS, to compare a combination to established monotherapy, and to provide comparative efficacy data for two commonly-prescribed drugs. (
  • While there was no substantial clinical benefit of combination therapy over monotherapy, we will continue to monitor these patients to see if the reduction in MRI lesion translates into a future clinical benefit," said Dr. Lublin. (
  • Oseltamivir/zanamivir combination therapy was as effective at suppressing oseltamivir- and zanamivir-resistant influenza viruses and the combination regimen inhibited viral replication at a level that was similar to the most effective monotherapy arm. (
  • Consider potential drug interactions when starting combination therapy with antiepileptic drugs 2018-05-29 00:00:00 Alternative monotherapy and adjunctive therapy are both valid options following failure of initial monotherapy with an antiepileptic drug (AED). (
  • Alternative monotherapy and adjunctive therapy are both valid options following failure of initial monotherapy with an antiepileptic drug (AED). (
  • Databases and trial registers were searched from inception to July 27, 2017, for randomized trials of (sub)acute or chronic back pain or sciatica participants that were administered combination drug therapy compared with monotherapy or placebo. (
  • We also report a significant 37 per cent relative reduction in the risk of death among people who received the combination drug therapy compared with monotherapy. (
  • Fixed-dose combinations in particular, may provide significant advantages over high-dose monotherapy, including enhanced therapeutic efficacy and reduced risk of drug resistance. (
  • A large regional database study from Italy demonstrated that initial combination therapy for newly diagnosed hypertension results in fewer major adverse cardiovascular events at one year compared to monotherapy. (
  • Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. (
  • Investigators from Milan performed an observational study comparing initial use of monotherapy vs. two-drug therapy to determine if CV outcomes were different at one year. (
  • In addition, the frequency of CV events in those on monotherapy was highest in the first month after starting therapy, decreasing incrementally until six months. (
  • The authors concluded that initial combination therapy is more effective at preventing CV events over one year than initial monotherapy. (
  • Third, combination therapy has been associated with better BP control for up to one year, probably because it reduces the inertia of titrating monotherapy. (
  • The latter involved finding patients who took monotherapy for some period and combination therapy for a different period and experienced at least one CV event. (
  • A clinically relevant field of research is the development of rational, biologically based multi-targeted therapy combinations which will block cancer cell escape from single target inhibition, such as the use of EGFR inhibitors in monotherapy. (
  • Researchers assessed the differences in effectiveness and treatment outcomes for patients with PsA receiving TNFi monotherapy or combination therapy with csDMARDs. (
  • The study analyzed persistence on TNFi monotherapy or combination therapy with TNFi and csDMARDS using the Kaplan-Meier method, and equality of survival using logrank tests. (
  • However, in the Italian cohort, the monotherapy group persisted longer ( P =.030) than the combination therapy group. (
  • Similarly, among the Italian/Swiss and Bath cohorts (n=1205) combined, there were no significiant differences in rates of change in the HAQ with monotherapy or combination therapy. (
  • Tumor necrosis factor inhibitor monotherapy versus combination therapy for the treatment of psoriatic arthritis: combined analysis of European biologics databases [published April 1, 2020]. (
  • The LTG/VPA combination was superior to VPA or LTG monotherapy, and CBZ/VPA, VPA/GBP, or CBZ/VPA/PHT combinations. (
  • Among 508 patients treated in a randomized multicenter trial, initial combination therapy plus either tapered prednisone or infliximab (Remicade) and other medications outperformed monotherapy in the first year, reported Yvonne P.M. Goekoop-Ruiterman, M.D., of the University of Leiden, and colleagues and other centers. (
  • An industry official said, 'Combination therapy has relatively low value added compared to monotherapy, but it can lead to stable sales by selling new drugs with the drugs already in market,' adding, 'Making breakthroughs in the development new drugs through combination therapy rather than monotherapy has become a new strategy for global biopharmaceutical companies. (
  • Type 2 diabetes mellitus (T2DM) management is complex, with few patients successfully achieving recommended glycemic targets with monotherapy, most progressing to combination therapy, and many eventually requiring insulin. (
  • The purpose of these combinations is often to ensure optimal efficacy and to reduce adverse effects that may arise from monotherapy. (
  • In this context, combination therapy with one drug for hypoxic/glycolytic tumors and another for oxygenated tumors (where oxidative phosphorylation is activated) may be more favorable than monotherapy. (
  • He argued that it is an "illusion to think that monotherapy with any antiretroviral agent will have a major and lasting impact on this disease" because the development of drug resistance significantly lowers the efficacy of treatment. (
  • These combinationsof protease inhibitors and other anti-HIV medications, called highlyactive antiretroviral therapy (HAART), also decreased the amount ofHIV in the patients' blood. (
  • Treatment of malaria in HIV-infected individuals receiving antiretroviral therapy (ART) poses significant challenges. (
  • Is the Subject Area "Antiretroviral therapy" applicable to this article? (
  • Objectives: Rapid initiation of antiretroviral therapy (ART) is important for individuals with high baseline viral loads, such as in primary HIV-1 infection (PHI). (
  • We recommend that the dual therapy with 1% PER and oral TMP/SMX be used and reserved in cases of multiple treatment failures or suspected cases of lice-related resistance to therapy. (
  • 6-10 Pediatricians and other pediatric health care workers are now faced with finding new strategies to combat drug resistance associated with HLI. (
  • the cancer essentially lost its drug resistance. (
  • Response of liquid biopsies to approved drugs can help show resistance, predict response. (
  • However, the pathway can become dysregulated in cancer, and in so doing, contribute to uncontrolled tumor growth and resistance to conventional cancer therapies. (
  • Genomic approaches may help identify molecular markers for resistance to artemisinins and their partner drugs. (
  • Monitoring antimalarial drug resistance: making the most of the tools at hand. (
  • Each antiviral suppressed the replication of influenza strains which were resistant to the other neuraminidase inhibitor, showing each drug does not engender cross-resistance to the other compound. (
  • These findings demonstrate that combination therapy with two agents that target the same viral protein through distinctly different binding interactions is a feasible strategy to combat resistance emergence. (
  • In addition, drug-related toxicities and drug resistance are rampant for these patients, spurring an urgent need for new therapy options. (
  • Compositions and methods for increasing drug bioavailability and/or preventing multi-drug resistance through inhibition of ABCG2 by xanthine compounds are disclosed. (
  • 8. The composition of claim 1, wherein the pharmaceutically active agent is an inhibitor of at least one protein associated with development of multi-drug resistance. (
  • 9. The composition of claim 8, wherein said at least one protein associated with development of multi-drug resistance is a P-glycoprotein, multidrug resistance-associated protein, or lung resistance-related protein. (
  • Surprisingly, the artemisinin component typically makes a negligible contribution (≪0.0001%) to the therapeutic capacity of the most widely used ACTs and only starts to make a significant contribution to therapeutic outcome once resistance has started to evolve to the partner drugs. (
  • The main threat to antimalarial drug effectiveness and control comes from resistance evolving to the partner drugs. (
  • In cancer research, the possibility to profile cellular responses to an extensive collection of anti-cancer compounds enables a systematic means to repurpose existing drugs to new indications, identify druggable vulnerabilities in various types of cancer cells and to functionally investigate cellular pathways behind drug sensitivity or resistance. (
  • In order to prevent widespread resistance, antimalarial combination therapies (ACTs) have been deployed and a World Antimalarial Resistance Network has been established as a means of anitimalarial drug resistance surveillance. (
  • Studies of drug disposition and drug efficacy (PK/PD evaluations) are essential to understanding why drugs work as antimalarials as they illustrate issues with drug resistance, drug safety and drug toxicity that are critical to finding the appropriate drug dose for patients. (
  • Unfortunately, as with all current therapies for AML, most patients treated with venetoclax will eventually relapse due to development of resistance mechanisms. (
  • 4-8 To overcome the development of resistance, rational combinations that target distinct antiapoptotic pathway members and can potentially lead to synergy have become an area of burgeoning translational research. (
  • Ongoing investment by major manufacturers in research and development activities in order to create combination drugs that help combat antiviral resistance is also boosting the outlook of the global antiviral combination therapy industry. (
  • A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers. (
  • By precisely identifying the mechanism by which elevated levels of YAP promote the survival of cancer cells, the new work points the way to combination therapies that may overcome resistance to individual targeted drugs, the scientists said. (
  • Though cancer drugs aimed at specific genetic mutations have had some success in recent years, most patients who have a good initial response eventually develop resistance to these therapies, most likely because cancer cells engage alternative survival mechanisms that lie outside the biological pathways targeted by the drugs. (
  • Though oncologists have the option of switching to a different targeted drug after resistance takes hold, many cancer researchers believe that a better strategy would be to forestall cancer cells' eventual escape routes by using customized combinations of targeted drugs at the outset of therapy. (
  • Instead of trying to figure out why patients have developed resistance after it has emerged, we need to decipher what survival tactic tumor cells will be most dependent on when they are challenged with targeted therapy," said the senior author of the study, Trever Bivona , MD, PhD, UCSF assistant professor of medicine and a member of the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC). (
  • These programmes also reduced prices of ACTs, improved market share of ACTs and reduced the use of older antimalarial drugs among febrile children under five years of age. (
  • As chloroquine and sulfadoxine-pyrimethamine (SP) are replaced by more effective artemisinin-based combination therapies (ACTs), strategies for monitoring (and, if possible, deterring) drug-resistant malaria must be updated and optimized. (
  • Current guidelines for malaria treatment advocate use of artemisinin-based combination therapies (ACTs). (
  • Recently, subsidized artemisinin-based combination therapies (ACTs), a first-line medication for uncomplicated malaria, were made available in these drug shops in Tanzania. (
  • This study assessed the prevalence of malaria among and purchase of ACTs by drug shop clients in the setting of a national ACT subsidy program and sub-national drug shop accreditation program. (
  • The low proportion of persons with malaria purchasing ACTs, and the high proportion of ACTs going to persons without malaria demonstrates a need to better target who receives ACTs in these drug shops. (
  • The National Malaria Control Program identified the accredited drug dispensing outlet (ADDO) program as a private sector mechanism to supplement the distribution of subsidized artemisinin-based combination therapies (ACTs) from public facilities and increase access to the first-line antimalarial in rural and underserved areas. (
  • The program established a supply of subsidized ACTs, created a price system with a cost recovery plan, developed a plan to distribute the subsidized products to the ADDOs, trained dispensers, and strengthened the adverse drug reactions reporting system. (
  • Importantly, the transition to ACTs has been accomplished in an environment where the safety and efficacy of the drugs and the quality of services are being monitored and regulated. (
  • Having reliable forecasts is critical now for producers, malaria-endemic countries and agencies in order to adapt production and procurement of the artemisinin-based combination treatments (ACTs), the new first-line treatments of malaria. (
  • This study uses drug consumption to provide elements to help estimate quantities and financial requirements of ACTs. (
  • Most current antimalarial drugs are combinations of an artemisinin plus a 'partner' drug from another class, and are known as artemisinin-based combination therapies (ACTs). (
  • Pancreatic tumors recruit a thick layer of connective tissue called stroma that hardens the tumor and acts like a shield," says Olive, whose previous research first uncovered how the stroma makes it difficult for chemotherapy drugs to reach malignant cells. (
  • Although more evaluation is needed to find out if these combinations would be effective for patients, their activity at low concentrations in the lab is promising, suggesting that they may have clinical activity at levels that are not toxic," said Brennan-Krohn. (
  • We are encouragedthat some patients having favorable immune responses to this new drugtherapy may be able to stop standard anti-CMV retinitis medication fora period of time. (
  • Between 60 and 90 patients with chronic hepatitis C will be enrolled in a study of the combination of alpha interferon and ribavirin for 12 months with early discontinuation of therapy and randomization to receive either ribavirin alone or placebo for patients who do not respond within 6 months of starting therapy. (
  • During the initial 24-week period of combination therapy, patients will be seen in the outpatient clinic for medical interview, physical examinations and blood tests at 2 to 4 week intervals. (
  • At this point, ribavirin and placebo will be stopped (unless the patient has had a clear histological and biochemical response to therapy) and patients will be monitored with outpatient visits at 8 week intervals for another 6 months. (
  • If the biochemical response is maintained, patients will continue on therapy for one year and then undergo repeat medical evaluation and liver biopsy. (
  • Patients must not have received the combination of alpha interferon and ribavirin in the past. (
  • Rather, debate has centered on the antihypertensive drug class that provides the greatest benefit to various subgroups of patients. (
  • These patients will require combination therapy to achieve blood pressure control to the level of 140/90 mm Hg or less. (
  • Given the newer, more appropriate lower target blood pressures for high-risk patients with hypertension, combination drug therapy will play an increasingly important role in attaining goal blood pressure. (
  • For example, the United Kingdom trial 7 found that almost 30 percent of patients with type 2 diabetes and hypertension required three or more drugs to achieve an on-treatment blood pressure of 143/81 mm Hg (a systolic pressure fully 13 mm Hg higher than recommended in JNC VI 3 ). (
  • The move to combination antihypertensive drug therapy, even as initial therapy, in high-risk patients with hypertension (particularly those with blood pressures in excess of 170/105 mm Hg, diabetes mellitus or renal insufficiency) is long overdue. (
  • The research evaluates drug delivery but does not assess whether the patients had confirmed (parasite-diagnosed) malaria. (
  • A new BJU International study found that combination CC+AZ therapy is safe and effective for patients with elevated estradiol or a low testosterone/estradiol ratio. (
  • Researchers admit that the initial trial of the cladribine-alemtuzumab combination dealt with a very small number of patients and that larger studies will have to be done per standard medical protocol to confirm safety and efficacy. (
  • 87 patients in the combination group and 91 in the single-therapy group completed the trial. (
  • After a year, remission was achieved in 24 of 97 patients with combination therapy, and 11 of 98 with single-drug therapy (p=0.011). (
  • Clinical improvement (American College of Rheumatology criteria of 50% clinical response) was achieved after 1 year in 68 (75%) patients with combination therapy, and in 56 (60%) using single-drug therapy (p=0.028), while at the 2-year visit 69 and 57 respectively (71% vs 58%, p=0.058) had clinically improved. (
  • The combination strategy as an initial therapy seems to increase the efficacy of the treatment in at least a proportion of patients with early rheumatoid arthritis. (
  • NUTLEY, N.J., January 07, 2008 /PRNewswire/ -- Data published in this week's New England Journal of Medicine show that oral Xeloda(R) (capecitabine) and oxaliplatin in combination with epirubicin is a comparable alternative to infused fluorouracil (5-FU) and cisplatin with epirubicin in patients with previously untreated, advanced esophagogastric cancer. (
  • In the study, median survival time was longer and one-year survival was higher among patients taking the Xeloda, epirubicin and oxaliplatin combination compared to the standard treatment, epirubicin, cisplatin and 5- FU. (
  • Our research suggests that oral Xeloda and oxaliplatin can provide patients with a valuable option over the standard regimen of infused fluorouracil and cisplatin in combination with epirubicin as a first-line therapy for esophagogastric cancer," stated lead investigator Professor David Cunningham, M.D., F.R.C.P., Head of the Gastrointestinal and Lymphoma Units of the Royal Marsden Hospital National Health Service Foundation Trust of Surrey and London. (
  • ATLANTA--A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology. (
  • The patients were previously untreated when they received the Rev/Vel/Dex combination. (
  • While these are the first results from trials of Rev/Vel/Dex given as initial, first-line therapy for the blood cancer, the combination has already been shown effective for multiple myeloma patients who had relapsed following successful treatment or who had not responded to standard therapies. (
  • Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy. (
  • Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease -- a point when many patients currently run out of options. (
  • Our findings, in combination with results from another FDA-mandated safety study, are very reassuring to those of us who treat asthmatic patients. (
  • In this multicenter, double-blind, 26-week study, the scientists evaluated whether the addition of formoterol to budesonide maintenance therapy increased the risk of serious asthma-related events in patients with moderate to severe asthma. (
  • Of the 11,693 patients enrolled in the study, an asthma-related event occurred in 43 patients who received the combination therapy of budesonide and formoterol and in 40 patients who received only budesonide. (
  • Ten patients developed adverse reactions, seven receiving active drug and three patients receiving placebo. (
  • In patients treated with cytotoxic drugs granulocytopenia and septicemia are commonly seen. (
  • We believe that a combination drug-device approach to deliver targeted chemical denervation may indeed provide a therapy that can help those patients whose hypertension is poorly controlled with medication alone. (
  • drug-device combination therapies to improve the lives of patients with uncontrolled neurological diseases, announced today the closing of a $3 million Series A financing by institutional investors Granite Point Capital Management, L.P., and Vivo Capital, LLC. (
  • Cerebral Therapeutics is currently exploring direct intracerebroventricular (ICV) administration of a proprietary formulation of an anti-epileptic drug to potentially enhance efficacy and reduce toxicity in adult patients with refractory epilepsy. (
  • We believe we are now well positioned to advance our potentially life-changing therapy for adult patients with refractory epilepsy while establishing a strong foundation for future therapeutic opportunities in other uncontrolled neurological conditions. (
  • Objective To compare methotrexate based disease modifying antirheumatic drug (DMARD) treatments for rheumatoid arthritis in patients naive to or with an inadequate response to methotrexate. (
  • Design Systematic review and Bayesian random effects network meta-analysis of trials assessing methotrexate used alone or in combination with other conventional synthetic DMARDs, biologic drugs, or tofacitinib in adult patients with rheumatoid arthritis. (
  • Objective To determine whether intensive combinations of synthetic disease modifying drugs can achieve similar clinical benefits at lower costs to high cost biologics such as tumour necrosis factor inhibitors in patients with active rheumatoid arthritis resistant to initial methotrexate and other synthetic disease modifying drugs. (
  • Participants Patients with rheumatoid arthritis who were eligible for treatment with tumour necrosis factor inhibitors according to current English guidance were randomised to either the tumour necrosis factor inhibitor strategy or the combined disease modifying drug strategy. (
  • To study the impacts of 1) the delay from the onset of symptoms to the institution of disease-modifying antirheumatic drug (DMARD) therapy, 2) two treatment strategies (treatment with a combination of DMARDs or with a single drug), and 3) the presence of HLA-DRB1 alleles (shared epitope) on the prediction of disease remission after 2 years in patients with early rheumatoid arthritis (RA). (
  • In the FIN-RACo (FINnish Rheumatoid Arthritis Combination therapy) trial, 195 patients with recent-onset RA (median duration 6 months) were randomly assigned to receive either 1) a combination of DMARDs (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone) or 2) a single DMARD with or without prednisolone. (
  • The delay to therapy (cut point of 4 months) was the only significant predictor for remission in patients treated using the single-DMARD strategy, while no variable was a significant predictor for remission in those treated using the combination-DMARD strategy. (
  • More recently, over the past several years, there has been an explosion in the available information related to the properties of drugs and the biomedical parameters of patients. (
  • For the drugs, hundreds of 2D and 3D molecular descriptors for medicines are now available, while for patients, large data sets related to genetic/proteomic and metabolomics profiles of the patients are now available, as well as the more traditional data relating to the histology, history of treatments, pretreatment state of the organism, etc. (
  • The goal of this rule-based expert system, with ∼600 rules, was to provide physicians therapy recommendations for patients with bacterial infections [3]. (
  • The market for multitargeted therapies exhibits impressive growth due to effective treatment options, use of small molecule drugs effective against multiple targets and rise in the number of patients suffering from complex diseases such as cancer. (
  • Switching from enfuvirtide to raltegravir in the treatment of HIV-infected patients who sustain viral suppression with a combination therapy including enfuvirtide (or : with an enfuvirtid. (
  • In the addicts, combined therapy effected a more rapid mean clinical response (defervescence and normalization of leukocyte count) and a reduced duration of bacteremia in patients with right-sided endocarditis. (
  • Our lab uses machine learning to predict an optimal therapy for HIV patients, based on the viral genotype. (
  • We conducted a systematic review to investigate the effects of combination drug therapy in patients with low back pain and/or sciatica on pain, disability, and adverse events. (
  • Led by Associate Professor Georgina Long of Melanoma Institute Australia and The University of Sydney, the finding affirms accumulating evidence of the effectiveness of targeted combination therapies in extending life and halting disease progression in patients with cancers that carry genetic mutations that resist single-drug therapies. (
  • Patients were between the ages of 40 and 80 years and were compliant with therapy. (
  • Since most combination therapy in Italy used fixed-dose combinations, patients who received multiple individual prescriptions were excluded. (
  • Of these patients, 83% started therapy on one drug and 17% started therapy on two drugs. (
  • It is noteworthy in this study that only about one in five patients started combination therapy despite previous positive data and the recommendations of national guidelines. (
  • While new immune therapies have helped improve survival rates, some patients are unresponsive to existing treatment regimens. (
  • They used mouse models with growing, drug-resistant cancer cells collected from human patients. (
  • Combination single-pill antiplatelet therapy, which may reduce daily pill burden for patients after PCI with DES, demonstrated similar efficacy to separate dual-pill antiplatelet therapy. (
  • Although this new combination antiplatelet pill has shown biological effects similar to those of typical dual antiplatelet medications in laboratory tests, there is a lack of clinical data in patients who had undergone DES implantation. (
  • This study was performed to compare the effects of three different lipid-lowering therapies (statins, ezetimibe, and colestimide) on lipoprotein lipase and endothelial lipase masses in pre-heparin plasma (pre-heparin LPL and EL mass, respectively) from patients with familial hypercholesterolemia (FH). (
  • The pre-heparin LPL and EL masses were measured in fresh frozen plasma drawn and stored at various time points during coadministration of the three drugs from patients with heterozygous FH harboring a single mutation in the LDL receptor ( n = 16, mean age 63 years). (
  • Therefore, we compared the effects of three different lipid-lowering therapies (statins, ezetimibe, and colestimide) on LPL and EL mass in pre-heparin plasma (pre-heparin LPL and EL mass, respectively) in patients with FH. (
  • However, EGFR-targeted therapies have a significant clinical activity only in a subgroup of cancer patients whose tumors express the EGFR. (
  • 1. Female patients, age 16 years and older with epithelial ovarian, primary peritoneal or fallopian tube cancer who have relapsed within 12 months of previous platinum-based therapy. (
  • About 51% to 79% of patients with psoriatic arthritis receive tumor necrosis factor inhibitor combination therapy with methotrexate. (
  • Using 5 biologic cohorts investigated between 2000 and 2015, the researchers analyzed data from patients across the ATTRA registry in the Czech Republic, the Swiss Clinical Quality Management PsA registry, the Hellenic Registry of Biologics Therapies in Greece, the University of Bari, Italy, PsA biologics database, and the Bath, United Kingdom, PsA cohort. (
  • Analysis of the Swiss ( P =.002), Greek ( P =.021), and Bath ( P =.014) cohorts revealed that compared with patients who received only TNFis, those who received TNFis in combination with the most widely used csDMARD, methotrexate, had longer drug survival. (
  • Findings from the study also showed that a lower percentage of patients receiving both TNFi and methotrexate discontinued combination therapy potentially because of inhibition of the development of antidrug antibodies from the combination of drugs. (
  • The results of large clinical trials have led physicians and patients to question the safety of hormone therapy for menopause. (
  • On current data there is not sufficient evidence that the combination of steroids with antiviral drugs has a benefit for the patients. (
  • The combination therapy with prednisone or infliximab was also better at suppressing progression to joint damage in the early stages of disease, but by two years about 42% of patients in all treatment groups were in remission, and many were being maintained on only one disease-modifying antirheumatic drug (DMARD), or none, the authors noted. (
  • The results of the long-running BeSt (a Dutch acronym for Behandel-Strategieen, or 'treatment strategies') study show that 'if clinicians are allowed the flexibility to change or escalate therapy, the vast majority of patients will be doing very well at two years regardless of which initial therapy they received,' noted James R. O'Dell, M.D., of the University of Nebraska Medical Center in Omaha, in an accompanying editorial. (
  • The study also demonstrates that 'most patients can achieve excellent outcomes when clinicians escalate therapy until the patient achieves a low level of disease activity' and that 'therapy should be individualized because patients with excellent responses were receiving a wide variety of DMARDs and combinations of drugs,' Dr. O'Dell added. (
  • The authors found that patients in both groups 3 and 4 (started on combination therapy) had more rapid clinical improvement and regained physical function (as gauged by change in Health Assessment Questionnaire score) significantly earlier during the first year than the patients in groups 1 and 2. (
  • MSD is planning to use the drug in clinical trials for gastric and colorectal cancer patients. (
  • MSD announced early this year that it will administer Tanibirumab with its own developed drug Keytruda to brain tumor and metastatic breast cancer patients in tentative doses. (
  • Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. (
  • For patients with metastatic prostate cancer, the 5-year survival rate of 31% points to a need for novel therapies and improvement of existing modalities. (
  • This novel combination approach will be tested in upcoming clinical trials for patients with lung cancer at MD Anderson. (
  • Testing patients for ZEB1 may identify those likely to respond to MEK inhibitors alone, versus those requiring combination therapy to chemosensitize their tumor cells. (
  • In patients with early rheumatoid arthritis (RA), how does treatment with a combination of disease-modifying antirheumatic drugs (DMARDs) compare with a single DMARD for prevention of work disability? (
  • After 2 years, the drug treatment strategy was no longer restricted and patients with inadequate response to single DMARD therapy were allowed to switch to combination DMARD therapy. (
  • In patients with early rheumatoid arthritis, aggressive initial treatment with a combination of DMARDs reduced the number of days of sick leave and overall work disability at 5 years more than therapy with a single DMARD. (
  • Systematic profiling of the relative activity of hundreds or thousands of drugs at several concentrations in a large number of cancer samples or cell types facilitates the stratification of cancer patients and disease subtypes, as well as development of personalized treatment strategies for clinical applications. (
  • However, high-throughput drug testing experiments often result in high-dimensional sample-dose-response matrices, with inherent measurement noise and technical variability, which hinders many downstream analyses, such as those aimed at detecting differential drug sensitivities or clustering of patients and/or drugs based on their selective response patterns. (
  • A targeted three-drug combination therapy resulted in median overall survival of nine months for patients with advanced bowel cancer compared to 5.4 months for current standard-of-care treatment, showed the results of a phase-3 clinical trial. (
  • The data suggested that the three-drug combination, encorafenib, binimetinib and cetuximab, should replace chemotherapy for patients with metastatic colorectal cancer who have a BRAF gene flaw. (
  • Based on the drug's safety profile and our own findings, there's a good rationale for testing PTC596 in combination with standard therapy in patients with pancreatic cancer," says Olive. (
  • The combination of antiviral medicines with antibiotics has been shown to have positive potential for patients to reduce coronavirus symptoms. (
  • Reports on the work of researchers who used brain images to correlate cocaine-addicted patients' regional brain responses to drug cues with their outcomes in subsequent treatment. (
  • Artificial intelligence in drug combination therapy Tsigelny, Igor F 2018-02-09 00:00:00 Abstract Currently, the development of medicines for complex diseases requires the development of combination drug therapies. (
  • 2018). Combination Drug Therapy for the Management of Low Back Pain and Sciatica: Systematic Review and Meta-Analysis. (
  • SAN DIEGO, CA - February 12, 2018: Igor F. Tsigelny, Ph.D., Co-founder and Chief Science Officer at CureMatch ® , is the author of " Artificial intelligence in drug combination therapy " in Briefings in Bioinformatics Journal 1 . (
  • We conducted a review of the effect of subsidising artemisinin-based combination therapy (ACT) drugs for malaria. (
  • A drug combination of artemisinin-naphthoquine should be considered for the treatment of children with uncomplicated malaria in settings where multiple parasite species cause malaria according to Tim Davis from University of Western Australia, Fremantle, Australia and colleagues in new research published in this week's PLOS Medicine . (
  • The authors compared the current recommended therapy for uncomplicated malaria in children in Papua New Guinea, artemether-lumefantrine, with a different combination therapy, artemisinin-naphthoquine. (
  • Artemether-lumefantrine (AL) is one of the artemisisnin-based combination therapies recommended for treatment of malaria. (
  • The drug combination is highly efficacious against sensitive and multidrug resistant falciparum malaria. (
  • Treatment of malaria in HIV-infected individuals receiving ART poses significant challenges with gaps in the knowledge of ART and ACT drug-drug interactions and their consequences. (
  • Throughout Africa, many people seek care for malaria in private-sector drug shops where diagnostic testing is often unavailable. (
  • Malaria is common amongst persons presenting to drug shops with a complaint of fever. (
  • In Tanzania, many people seek malaria treatment from retail drug sellers. (
  • There is no ideal method to quantify drug requirements for malaria. (
  • To complement malaria morbidity-based forecasts this study used a consumption approach to produce forecasts of volumes (primarily for drug manufacturers and procurement agencies) and financial requirements (of primary interest for donors and governments). (
  • The analysis was limited to first-line drugs in use based on the treatment guidelines at the time of the study, essentially chloroquine and sulphadoxine/pyrimethamine for uncomplicated malaria, and quinine for more severe malaria. (
  • They are the frontline drugs in treating human malaria infections. (
  • This eBook illustrates how currently available combination antimalarial drugs can be optimized for effective malaria treatment. (
  • For example, based on gene alterations, it would be not unreasonable for a cancer treatment regimen to require six or more drugs (each targeting a particular genetic alteration), and when one considers the multiple possible dosing regimens, the number of potential combinations rapidly multiplies, achieving numbers as high as 1011 [2]. (
  • Clinically significant CYP-mediated drug-drug interactions are more likely to occur with non nucleoside reverse transcriptase inhibitors (NNRTs) and protease inhibitors- (PIs-) based ART regimens because these are substrates, inducers, and/or inhibitors of CYP enzymes which metabolize the majority of drugs and xenobiotics [ 3 ]. (
  • Single (nafcillin for 6 weeks) and combined (nafcillin for 6 weeks plus gentamicin for 2 weeks) drug regimens were compared in two separate multicenter prospective randomized trials. (
  • We aimed to evaluate the tolerability of four-drug regimens used in the Research in Viral Eradication of HIV-1 Reservoirs (RIVER) study. (
  • Methods: At enrolment, ART-naïve adult participants or those newly commenced on ART were initiated or intensified to four-drug regimens within 4 weeks of PHI. (
  • Factoring multiple possible dosing regimens, the number of potential combinations rapidly multiplies, achieving numbers as high as 1011. (
  • Many find the new drug regimens too demanding to take correctly, even though not doing so weakens the benefits of taking the drug. (
  • Artemisinin-based combination therapies have proven to be useful as a replacement for standard regimens. (
  • Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. (
  • This multicentre, randomised trial with 2-year follow-up sought evidence on the efficacy and tolerability of combination therapy (sulphasalazine, methotrexate, hydroxychloroquine, and prednisolone) compared with treatment with a single disease-modifying antirheumatic drug, with or without prednisolone, in the treatment of early rheumatoid arthritis. (
  • Combination therapy was better and not more hazardous than single treatment in induction of remission in early rheumatoid arthritis. (
  • Combination therapy in rheumatoid arthritis. (
  • The custom BAFF-R antibody is currently being tested as a therapy to treat autoimmune diseases and rheumatoid arthritis in two clinical trials. (
  • Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? (
  • LEIDEN, The Netherlands -- For early rheumatoid arthritis, aggressive combination therapy can slow progression to joint damage, investigators here found. (
  • Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. (
  • Randomized controlled trial (Finnish Rheumatoid Arthritis Combination Therapy trial). (
  • Global Combination Therapy Drug Market Report illustrates the present development status of Combination Therapy Drug along with the growth of Combination Therapy Drug expected during the forecast period during 2017-2022. (
  • ACT price subsidies were accompanied with activities (such as staff training at shops and pharmacies, community awareness and mass media campaigns) to promote appropriate use of antimalarial drugs in all except one study. (
  • Coverage so far has been low for a variety of reasons, including the lack of reliable forecasts of antimalarial drug volumes needed for both global and local consumption. (
  • Quantifying the pharmacology of antimalarial drug combination therapy. (
  • ORCID: and Kay, Katherine (2016) 'Quantifying the pharmacology of antimalarial drug combination therapy. (
  • In recent years, some Plasmodium strains have become increasingly resistant to all classes of conventional antimalarial drugs currently in use. (
  • It is, therefore, a handy reference for medical professionals and pharmacologists working on antimalarial drugs. (
  • The study's methods draw on the researchers' previous findings that combination therapy may be effective even when bacteria become resistant to colistin, which is considered a treatment agent of last resort that can punch holes in the tough outer shell of Gram-negative bacteria. (
  • Drugs that target pain at different levels can allow the caregiver to customize treatment according to the patient's specific needs. (
  • This diversification of the pain perception and exhibition explains why a broader range of molecularly different substances can be used for the treatment of different pain conditions and why in more recently several studies have described a much better efficacy of a precise multi-target combination therapy as compared to mono-therapy. (
  • increasing in frequency as people with AIDS live longer, with up to40% of all adults with AIDS eventually developing the disease.Standard treatment for CMV retinitis, which can cause blindness ifleft untreated, requires life-long medication with a variety ofanti-CMV drugs that can be cumbersome, costly, and toxic. (
  • Combination Therapy or Single Drug for CLL Treatment? (
  • 8 Typically, a preferred drug is chosen for initial treatment. (
  • The clinician is well advised to heed the important advice that Skolnik and colleagues 1 provide about the merits of combination antihypertensive drug treatment. (
  • To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. (
  • This study compared the efficacy of 3 different treatments for HLI and determined whether combination therapy reduced treatment failures. (
  • While it is not FDA-approved as a treatment for T-PLL, the drug nelarabine can also be used in some cases. (
  • 195 started the treatment (97 received combination and 98 single drug therapy). (
  • The boys in group one will take the medication until the age of 14 at which time they will stop taking the four drug combination and begin receiving the standard treatment for congenital adrenal hyperplasia. (
  • A post-marketing safety study mandated by the U.S. Food and Drug Administration has shown that a combination drug therapy for the treatment of asthma is safe and effective. (
  • The purpose of this study is to determine if a combination anti-HIV drug treatment regimen of indinavir plus lamivudine (3TC) plus zidovudine (ZDV) is effective in treating HIV and in reducing the chances of passing HIV from mother to child. (
  • Under the IND, Ablative Solutions plans to conduct a multi-center, double-blind, randomized, sham-controlled trial to evaluate its drug-device combination therapy for the treatment of persistent hypertension despite optimal medical treatment, in conjunction with antihypertensive medical therapy. (
  • The principal investigators (PIs) of the study are experienced thought leaders in the treatment of hypertension who have had leadership roles investigating renal denervation as a therapy for hypertension. (
  • The spatial-temporal synchronization of photothermal therapy and chemotherapy is highly desirable for an efficient cancer treatment with synergistic effect. (
  • These findings provide an excellent NIR laser regulated nanoplatform for combined cancer treatment with synergistic effect due to the synchronous chemo- and photo-thermal therapy. (
  • The treatment paired two chemotherapy drugs currently used to treat Ewing sarcoma (EWS) with experimental drugs called poly-ADP ribose polymerase (PARP) inhibitors that interfere with DNA repair. (
  • A clinical trial using the three-drug combination therapy detailed in this research is expected to open later this year for adolescents and young adults with EWS whose tumors have not disappeared with standard therapy or have returned after treatment. (
  • The study included 15 different treatment groups using different combinations and doses of IRN, TMZ and three PARP inhibitors currently in development for pediatric cancer treatment. (
  • Main outcome measure Primary outcome: reduction in disability at 12 months measured with patient recorded heath assessment questionnaire (range 0.00-3.00) with a 0.22 non-inferiority margin for combination treatment versus the biologic strategy. (
  • The investigators were successful in implementing a clinical trial comparing the effectiveness of a two-drug combination to treatment with a single drug," said Petra Kaufmann, MD, MSc, Associate Director for Clinical Research, NINDS. (
  • artificial intelligence, drug combination, combination therapy, machine learning, genomic profile Introduction It is becoming increasingly clear that targeted combination therapy is the treatment of choice in many complex human diseases, particularly those resulting from biological dysfunction driven by alterations/mutations in several genes or/and gene networks as is usually the case in cancer [1]. (
  • For example, an early AI application proposed for drug treatment strategy selection was the computer-based consultation system, MYCIN [3]. (
  • For example, multilayer (up to six layers) ANNs were used in combination with expert systems for the creation of a machine learning (ML) system for the diagnosis and treatment of hypertension [5]. (
  • The market for multitargeted therapies can be segmented on the basis of the molecules used in the treatment and novel approaches towards development of novel combination therapies against multiple targets. (
  • Researchers from Case Western Reserve University School of Medicine have developed a new combination treatment regimen that enhances the immune system's ability to kill leukemias that do not respond to standard treatments. (
  • The combination treatment could represent a promising new regimen for late-stage acute lymphoblastic leukemia, particularly benefitting adults who are unresponsive to existing options. (
  • The drug combination is the first and only treatment for women with estrogen-receptor-positive breast cancer to show such significant results in a randomized phase 3 trial. (
  • In addition, effectiveness assessment of TNFi treatment applied only to physical function and not to the other assessments, as a result of which efficacy of TNFi-only vs combination therapy with TNFi and csDMARDs did not include factors that might affect quality of life in PsA. (
  • This combination therapy was well tolerated, with similar levels of hypoglycemic adverse events in the empagliflozin and placebo groups over the 78-week treatment period. (
  • We propose that p53 gene therapy and chemotherapy, when combined, will provide superior tumor cell killing for the treatment of prostate carcinoma. (
  • Here, we combined AdRGD-PGp53 along with the chemotherapy drugs used in the clinical treatment of prostate carcinoma, mitoxantrone, docetaxel, or cabazitaxel. (
  • Targeted combination therapy is increasingly the choice treatment for many complex human diseases, particularly those resulting from genetic aberrations (such as cancer). (
  • The future of complex disease treatment is being driven by machine learning across rapidly growing datasets of drug and genomic/proteomic information," stated Tsigelny. (
  • Developing AI machine-learning systems allows CureMatch to score and rank Personalized Combination Therapy ® options to improve the precision of cancer treatment recommendations. (
  • Fong, DG & Lindor, KD 2000, ' Future directions in the medical treatment of primary sclerosing cholangitis: The need for combination drug therapy ', American Journal of Gastroenterology , vol. 95, no. 8, pp. 1861-1862. (
  • The study, published in the journal Nature Cell Biology , reports two drugs which are already approved, in another form, for the treatment of leukemia and other solid tumors, including the most aggressive type of skin cancer called melanoma. (
  • The study identifies a promising dual treatment for pancreatic cancer - one of the deadliest cancers - and I look forward to seeing these drugs tested. (
  • The researchers see this as further evidence that some cancers must be treated with multiple targeted drugs at the outset of treatment. (
  • First, the rate of accumulation of work disability days in the single-therapy group did not decrease after half the group switched to combination therapy, indicating that initial treatment was very important. (
  • An open-source and easily extendable implementation of the DSS calculation is made freely available to support its tailored application to translating drug sensitivity testing results into clinically actionable treatment options. (
  • The sad reality is that at present, pancreatic cancer therapy is lagging since there is no effective treatment for these tumors," says Ze'ev Ronai, Ph.D. , a professor in Sanford Burnham Prebys' Tumor Initiation and Maintenance Program and senior author of the study. (
  • Our study identifies a potential treatment combination that can immediately be tested against these aggressive tumors. (
  • L-asparaginase is FDA approved to treat certain leukemias, and the second drug, a MEK inhibitor, is approved for the treatment of solid tumors, including melanoma, a type of skin cancer. (
  • Drug A in doses of 0mg, 2.5mg, 5mg, 10mg and Drug B in doses of 0mg, 20mg, 40mg, 80mg were used in combination in the treatment of hypertension I and II. (
  • The Alzheimer's Disease Research Summit 2012: Path to Treatment and Prevention , held May 14-15, 2012, brought together leading experts on Alzheimer's disease and other complex diseases to identify research priorities and strategies needed to accelerate the development of successful therapies. (
  • The topics that were discussed included the current understanding of this complex disorder, the need for more basic research into the pathobiology of Alzheimer's disease, existing models and approaches to drug development, and new ideas to speed development of effective interventions for treatment and prevention. (
  • Actinium Pharmaceuticals, a biotechnology company specializing in ARCs, has performed translational work investigating the use of ARCs to deliver targeted radiation to AML cells that, in addition to delivering potent single-agent tumor-cell-killing activity, may resensitize cells to venetoclax treatment when used in combination with venetoclax ( Figure 1 ). (
  • Combination antiretroviral treatment aims to stop the virus from producing several copies of itself in the body. (
  • In response to therapy, the development of drug-resistant genetic changes plays a crucial role in therapeutic failure and it is considered difficult to discover a new potent drug combination after treatment failure. (
  • Describes research investigating the use of a treatment that combines vouchers and cognitive behavioral therapy as compared with the use of either treatment alone for marijuana abuse. (
  • The goal of this novel approach is to maximize efficacy while greatly reducing systemic drug exposure and enhancing drug regimen compliance. (
  • The drugs in the OB regimen are chosen from among the currently approved antiretrovirals and permitted newly approved/investigational antiretrovirals available in the countries where the study is implemented, and must consist of 3 to 5 drugs, including no more than 1 newly approved/investigational agent. (
  • Dual antiplatelet therapy with aspirin and clopidogrel is the standard regimen for prevention of thrombotic complications after DES implantation. (
  • Twenty (37%) started a four-drug regimen and 34 (63%) were intensified. (
  • To this end, low doses of 225 Ac-lintuzumab are being evaluated in combination with the chemotherapy regimen CLAG-M. (
  • Our preclinical results suggest Ewing sarcoma is particularly sensitive to this combination therapy, a possible indication that the tumor's DNA repair defect provides us with a much needed advantage to knock out tumor cells," Shelat said. (
  • The main focus of such therapies is to target all the tumor components and impair their function. (
  • This novel approach helps in elucidating the effects of therapeutic combination on each tumor component and results in unveiling of new anti-cancer mechanisms. (
  • A new study by scientists at Sanford Burnham Prebys Medical Discovery Institute have discovered a combination of two cancer-fighting drugs that successfully worked on pancreatic tumor in mice, shrinking them significantly, and paving the way for a speedy clinical trial designed to test their efficacy in humans. (
  • The second drug, the MEK inihibitor, blocks a key enzyme in this pathway, and prevents asparagine synthesis as well as asparagine-dependent protein synthesis in the tumor cells. (
  • To test these drug combinations in the BRAF-inhibitor resistant cells, the Herlyn laboratory used a tool they developed to simulate the real-world environment of human cells: 3-D melanoma tumor spheroids. (
  • The scientists then treated mice with a second drug that blocked the stress response pathway and shrank the pancreatic tumor. (
  • Pyrvinium pamoate (PP) is an FDA-approved classical anthelmintic, but is now attracting particular attention as an anti-cancer drug after recent findings of its potent cytotoxicity against various cancer cell lines only during glucose starvation, as well as its anti-tumor activity against hypovascular pancreatic cancer cells transplanted in mice. (
  • therefore, a new drug strategy against cancer cells under such tumor microenvironment-mimicking conditions is anticipated. (
  • For a pancreatic cancer drug to be effective, it needs to stick around long enough to seep past the stroma and accumulate in the tumor. (
  • Over the years, target blood pressure levels have not been the primary subject of debate in hypertension therapy. (
  • In this review, we discuss several AI methods that have been successfully implemented in several instances of combination drug therapy from HIV, hypertension, infectious diseases to cancer. (
  • In this system, the selection of hypertension drug combinations was accomplished by training the system using blood pressure time series measurements from ∼300 healthy subjects and 85 hypertensive subjects, which were divided to the learning set of data used for training the system and testing set of data [5]. (
  • Several rationales for using initial combination therapy for hypertension have been demonstrated. (
  • This 15-page intensive research review with 137 references explores several artificial intelligence (AI) methods that have been successfully implemented in combination drug therapy including HIV, hypertension, infectious diseases, and cancer. (
  • Principal Author of the study, Dr. Andreas Straube concluded by stating, "After the study, here is substantial clinical evidence that a multi-component therapy is definitely more effective than mono-component therapies as it boosts their effectiveness for pain relief. (
  • Although this protein, and others that work with it in the Ras pathway, would appear to be a perfect target for therapy, drugs that block their effect often have severe side effects that limit their effectiveness. (
  • The effectiveness of the therapy lies in its ability to target a pro-survival cell signaling pathway known as PI3K/AKT/mTOR, upon which the leukemia cells have become dependent. (
  • A world-first study in the New England Journal of Medicine heralds the effectiveness of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma. (
  • New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. (
  • Combination single-pill therapy can improve cost-effectiveness in a typical medical therapy. (
  • Recently, a combination single pill of aspirin and clopidogrel was developed, and it is well known that combination single-pill therapy can improve patient adherence and cost-effectiveness [ 5 , 6 ]. (
  • According to the pharmaceutical industry on October 9, overseas pharmaceutical companies are seeking cooperation with Korean companies to increase the effectiveness of their drugs by adding Korean drugs. (
  • This kind of combination therapy is beneficial to both domestic and foreign companies because it increases the effectiveness of the new drug over the individual drug administration. (
  • Because the new combination therapies have been studied for only 3-4 years, their long-term effectiveness is unknown. (
  • We therefore argue that public health policies be re-focussed to maximise the likely long-term effectiveness of the partner drugs. (
  • Research and Markets( ) has announced the addition of the 'Global Cephalosporin Drugs Market 2015-2019' report to their offering. (
  • The report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. (
  • In 2019, the global Combination Therapy Drug market was valued at US$ xx Mn, and it is expected to reach at US$ xx Mn at a CAGR of xx% during 2020-2028. (
  • In an MD Anderson-led study presented at the San Antonio Breast Cancer Symposium today, researchers presented new data about a combination drug therapy for women with metastatic breast cancer. (
  • Researchers at the National Institutes of Health have discoveredthat a combination of protease inhibitors and other anti-HIV drugsused to treat people with AIDS can prevent or delay the progression ofcytomegalovirus (CMV) retinitis, a potentially blinding eyecomplication of AIDS. (
  • A combination of two drugs, one already approved by the Food and Drug Administration , appears to be effective at shrinking pancreatic cancers in laboratory mice, according to a new study by researchers at the Stanford University School of Medicine . (
  • The researchers hope to soon test the drug combination in humans with pancreatic cancer. (
  • Now researchers have expanded its use to another deadly form of leukemia, drug-resistant T-cell prolymphocytic leukemia ( T-PLL ). (
  • ‌A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins. (
  • In the study, published in the journal Cancer Research, researchers combined the drug ABT-737 with another agent BEZ235. (
  • In the Phase III CombiRx trial, researchers led by Fred Lublin, MD , of The Mount Sinai Medical Center, sought to determine if Glatiramer Acetate (GA) and Interferon Beta-1a (IFN), the two most commonly-prescribed drugs for relapsing-remitting MS (RRMS), were more effective in combination than as monotherapies. (
  • Using their mouse disease model, the researchers showed that the combination of these two treatments enhanced killing of acute lymphoblastic leukemia cells-even if the disease was advanced. (
  • Building on earlier clinical trials, UCLA researchers have confirmed that the "breakthrough" drug palbociclib when used in combination with the traditional hormonal therapy letrozole delays progression of advanced breast cancer significantly and without the harsh side effects seen in some women prescribed letrozole alone. (
  • In 2013, after women in a clinical study led by UCLA researchers showed a dramatic improvement, the FDA granted palbociclib "breakthrough therapy" status, allowing it to be fast-tracked for approval. (
  • To reduce the toxicity and enhance the therapeutic efficiency of vinca alkaloids, many researchers have developed strategies such as using liposome-entrapped drugs, chemical- or peptide-modified drugs, polymeric packaging drugs, and chemotherapy drug combinations. (
  • Researchers at The University of Texas MD Anderson Cancer Center hope to dramatically improve these statistics with a novel combination therapy, targeting a newly discovered Achilles heel of aggressive and drug resistant cancers. (
  • Researchers and clinical staff are very hopeful about this type of combination therapy. (
  • Researchers have, therefore, stepped up efforts to revise atimalarial drug policies, develop new drugs, and implement new strategies to combat this disease. (
  • Drug combinations have demonstrated high efficacy and low adverse side effects compared to single drug administrations in cancer therapies, and thus draw intensive attentions from researchers and pharmaceutical enterprises. (
  • By simultaneously treating the cells with the cancer drug vemurafenib (Zelboraf), which specifically targets faulty BRAF proteins, the researchers were able to determine whether the drug was more effective when the action of other particular proteins was blocked. (
  • However, Lange was criticised for neglecting the needs of sex workers in the trials, and other researchers asserted that the concerns raised by activists are "entirely legitimate" since the known toxic effects of so-called 'pre-exposure' drugs will lead to liver failure and kidney disease, thereby killing people rather than protecting them. (
  • It covers more than 559 companies plus partners who are today developing 1365 combination therapy drugs in oncology drugs where of are active in developmental projects in cancer across 555 different targets. (
  • The challenge is to zero down drugs with molecular targets that restore the healthy state and result in lasting pain relief. (
  • The huge advantage of using such a fixed combination is that the active ingredients act on different but distinct molecular targets. (
  • Combination therapies are used against complex disorders that have multiple causes along with multiple targets and many small molecule drugs are capable of addressing multiple targets. (
  • Identification of novel combination-therapy drug targets, which work in synergy to mTOR inhibition using physiological human three-dimensional cancer models. (
  • Here, we report that the DGR combination exerts a more robust therapeutic effect than any one or two of the three individual compounds by hitting multiple targets in a rat model of HI. (
  • Investigative efforts to determine the role of events downstream of deoxy-HbS polymerization, such as endothelial cell activation, cellular adhesion, chronic inflammation, intravascular haemolysis and nitric oxide scavenging, have expanded drug targets which reverse the pathophysiology of SCD. (
  • Our results indicate that all drugs increase phosphorylation of p53, leading to improved induction of p53 targets. (
  • Here, we review accumulating knowledge on its working mechanisms and evaluate PP as a novel anti-cancer drug that targets mitochondrial respiration. (
  • Develop in vivo imaging agents (tracers for PET scans) to assess target engagement and the burden of brain pathology to enable successful drug development for existing and new therapeutic targets. (
  • Most drugs were effective in combinations when used in standard doses. (
  • Three of the 4 groups will contain capravirine in different doses combined with Kaletra and nucleosides and one of the groups will be a combination of Kaletra and nucleosides without the capravirine. (
  • Founded by experts in the fields of neurology, neurosurgery and drug delivery, the Company is pioneering the development of long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. (
  • Results: Among the various combinations of chemotherapeutic agents and radiation doses, concurrent chemoradiation therapy (CCRT) led to the highest rate of apoptosis and synergism. (
  • Fourth, by using low doses of multiple drugs with different adverse effect profiles, synergistic BP lowering is accomplished without increasing side effects. (
  • People who miss doses of any of their medications may put themselves at risk for developing drug-resistant strains of HIV. (
  • The objective of this study is to (1) To determine a region of optimum doses of Drug A and Drug B in combination while focusing on efficacy alone (2) To determine a region of optimum doses of Drug A and Drug B while focusing on efficacy incorporating important safety constraints. (
  • Response Surface Methodology (RSM) was used to find the doses of Drug A and Drug B which maximized efficacy, and a Probit-Normal Model was used to model the probability of the occurrence of edema. (
  • Treating illness promptly with artemisinin-based combination therapy (ACT) is likely to cure people and avoid the disease progressing to more severe forms and death. (
  • Ewing sarcoma tumors disappeared and did not return in more than 70 percent of mice treated with combination therapy that included drugs from a family of experimental agents developed to fight breast cancer, reported St. Jude Children's Research Hospital scientists. (
  • There is some evidence that this type of defect is present in other pediatric tumors, and we are actively investigating drug sensitivity in those cancers. (
  • The scientists took the patient data from previous studies and used them as the basis for a computational analysis, which showed that this combination was likely to be successful in shrinking a majority of pancreatic tumors. (
  • The experiment showed shrinkage of both melanomas and pancreatic tumors, but the scientists decided to focus first on clinical trials on the latter due to the complete lack of successful therapies at present. (
  • Reports of the drug trial described shrinking tumors and improved health. (
  • Yet seven months after therapy began the tumors returned and resumed growing. (
  • In fact, cells that became resistant to one type of BRAF drug became resistant to all of them, which suggests that the cells were biochemically 'rewired' in such a way that they no longer needed BRAF to form tumors. (
  • Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice-supporting the immediate evaluation of the drugs in a clinical trial. (
  • U.S. Food and Drug Administration (FDA)-approved versions of the compounds are used today to treat certain leukemias and solid tumors, including melanoma. (
  • In the study, the scientists used a drug called L-asparaginase to starve pancreatic tumors of a key nutrient, asparagine-an amino acid required for protein synthesis. (
  • They also tested PTC596 in combination with gemcitabine and another drug commonly used to treat pancreatic cancer, nab-paclitaxel, using human pancreatic tumors grown in mice. (
  • This combination further enhanced efficacy, making the tumors shrink outright. (
  • The primary outcome showed mean falls in scores on the health assessment questionnaire of −0.30 with the tumour necrosis factor inhibitor strategy and −0.45 with the alternative combined drug strategy. (
  • Some of these combination therapy trials show promising preliminary results with synergistic anti-tumour effects in vivo. (
  • Importantly, multicellular tumour spheroids display drug response and resis-tance characteristics closely matching those regularly seen in vivo. (
  • Importantly, we will use a collection of 1200 chemical compounds, which is commercially available and contains only already approved drugs for the clinic to re-evaluate these known drugs for their potential anti-tumour efficacy when combined with rapamycin. (
  • This study builds on a decade of research into the tumour biology of BRAF-mutated colorectal cancer, and reflects a rationale combination to address the vulnerabilities unique to this tumour," said principal investigator Scott Kopetz, Associate Professor at the University of Texas MD Anderson Cancer Center in the US. (
  • Multitargeted Therapies Promiscuous Drugs and Combination Therapies Market is Segmented by novel combination therapies such as multitargeted protein kinase inhibitors are used in treating chronic myelogenous leukemia and synthetic lethality used for treating combination of mutations in two or more genes leading to cell death. (
  • In addition to the identification of new effective drug combinations we will thereby discover novel pathways, which drive cancer development and will focus on the molecular mechanisms be-hind. (
  • It is, therefore, felt that combinations of EGFR inhibitors and other novel agents, which is based on the mechanistic knowledge of complementary signaling pathways whose concerted inhibition would efficiently block cancer cell growth, is the rationale therapeutic approach. (
  • Some of these pathways [i.e., mammalian target of rapamycin (mTOR), vascular endothelial growth factor receptor (VEGFR), ras/mitogen-activated protein kinase (MAPK) signaling, or insulin like growth factor receptor (IGFR)] which are functionally related to the activity of the EGFR will be discussed in this review to provide a scientific rationale for the combination of drugs which target these pathways with anti-EGFR agents. (
  • To find out which alternate pathways the drug-resistant cells use, Villanueva and her colleagues looked for signs of increased activation among proteins along the pathways BRAF uses, as well as other pathways. (
  • Generate new experimental models (e.g., different animal species, human induced pluripotent stem [iPS] cells, in silico models) that better simulate the multifactorial etiology of Alzheimer's disease and use these models to identify modulators of disease pathways and to assess combination treatments which may be required to defeat this disease. (
  • Herewith, we demonstrated the preparation, characterization and in vitro antitumor effects of Ara-C and DNR loaded GP-PLGA-modified bacterial magnetosomes (BMs) (ADBMs-P). The results show that this new system is stable and exhibits optimal drug-loading properties. (
  • Drug combination therapy has been an area of interest for a while, for example the classical work of Loewe devoted to the synergism of drugs was published in 1928-and it is still used in calculations for optimal drug combinations. (
  • Of note, the classical work devoted to the synergism of drugs by Loewe published in 1928 is still being used in calculations for optimal drug combinations. (
  • CureMatch's primary objective is to determine optimal combinations of anticancer drugs. (
  • Protease inhibitors are aclass of promising drugs recently introduced that, when taken withother HIV-fighting medications, have shown success in prolonging thelives of people with AIDS. (
  • Nucleoside reverse transcriptase inhibitors do not undergo CYP-mediated metabolism and are less likely to cause CYP-mediated drug interactions. (
  • In a so-called targeted therapy approach, scientists aim to find chemical inhibitors against specific molecules (proteins, often enzymes), which are aberrantly activated in human carcinoma to fight against cancer. (
  • Some new clinical studies use mTOR inhibitors in combination with either standard chemotherapy or other targeted therapy approaches. (
  • Our aims were to evaluate the antiviral activity of two neuraminidase inhibitors (oseltamivir and zanamivir) as combination therapy against H1N1 influenza A viruses, as these agents bind to the neuraminidase active site differently: oseltamivir requires a conformational change for binding whereas zanamivir does not. (
  • A number of clinical trials with EGFR inhibitors in combination with classic cytotoxic agents have been undertaken with both interesting and disappointing results. (
  • Maria Pia Morelli, Jennifer Spratlin and S. Gail Eckhardt, " Combination of Anti-EGFR Drugs with Anti-Angiogenic or Other Signal Transduction Inhibitors as a Rational Approach to Cancer Therapy", Current Cancer Therapy Reviews (2007) 3: 284. (
  • Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. (
  • Sodium glucose cotransporter 2 (SGLT2) inhibitors are an emerging class of antidiabetes agents with an insulin-independent mechanism of action, making them suitable for use in combination with any other class of antidiabetes agents, including insulin. (
  • HAART is also referred to as "drug cocktails" and includes drugs such as protease inhibitors . (
  • The good news is that drugs are being developed to work in combination with BRAF inhibitors, which our data clearly shows is our best option if we intend to beat advanced melanoma. (
  • According to the World Health Organization, cases of the disease continue to rise, which has helped spur research into therapies such as BRAF inhibitors. (
  • To study how melanoma responds to BRAF inhibitors, the Herlyn lab took melanoma cells with the BRAF mutation and tested them against a variety of anti-mutant BRAF drugs. (
  • As predicted, a combination of these two inhibitors killed BRAF-resistant melanoma cells in the Wistar 3-D model. (
  • Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a drug, reaction to a drug or drug abuse. (
  • Our study showed no significant increase in serious adverse events in the combination therapy," said Stephen Peters, M.D., Ph.D., professor of pulmonary, critical care, allergy and immunologic diseases at Wake Forest Baptist Medical Center and lead author of the study. (
  • Triple therapy had statistically fewer withdrawals due to adverse events than methotrexate plus infliximab. (
  • These profiles can be assessed both in terms of their expected efficiency in a disease of interest and in terms of potential adverse drug interactions with each other. (
  • To enhance therapeutic efficacy and reduce adverse effects of traditional Chinese medicine (TCM), practitioners often prescribe a combination of plant species and/or minerals called formulae. (
  • However, adverse effects still occur with combination therapies. (
  • In research published today in the journal Nature Communications, Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy. (
  • Their study, published today in Science Translational Medicine, reveals how lung cancers with KRAS mutations bypass targeted treatments, and how to thwart their evasion strategy with new drugs. (
  • Children with a bone age of 1 to 2 years may enroll in the protocol for optimization of conventional therapy, but will not be randomized to a study arm until the bone age reaches 2. (
  • Thus, computational approaches are clearly required, and there are currently a number of artificial intelligence (AI) methods being used for optimization of combination therapies. (
  • Computational approaches are clearly required in the optimization of combination therapies, and many artificial intelligence (AI) methods are being utilized. (
  • However, there is a little evidence about the efficacy and tolerability of combination single-pill antiplatelet therapy after percutaneous coronary intervention (PCI) with drug-eluting stents (DES). (
  • They can be as potent and effective as prescription drugs without unwanted side effects. (
  • ACT drugs are available at shops and pharmacies, but these drugs are expensive and people often choose cheaper, older, less effective drugs instead. (
  • The Global Fund and other international organisations have therefore decided to subsidise the cost of ACT drugs so that people can buy them from shops and pharmacies at prices similar to, or lower than, those of the older, less effective drugs. (
  • Our findings indicate that a combination of 1% PER and TMP/SMX is an effective alternative therapy for HLI. (
  • In the study of 51 men, AZ provided an effective means for lowering estradiol levels and increasing the testosterone/estradiol ratio following the initiation of CC therapy. (
  • The combination of drugs in this study may be more effective than ZDV alone. (
  • The initiation of triple combination therapy, including a protease inhibitor indinavir, during gestation may be the most effective in reducing maternal virus load prior to delivery, thereby potentially benefitting both mother and child. (
  • A paradigm shift has been observed with respect to the development of effective therapies involving the use of complementary drug combinations. (
  • Rapid development of medical device and pharmaceutical industry have enabled the development of devices which incorporate drugs into it for effective application. (
  • The use of existing drugs for new therapies is advantageous in many respects, such as the knowledge of the effective drug levels and known side effects. (
  • This study examined the most effective combination methods of CTX and RT against NSCLC. (
  • CTx followed by RT was the most effective combination when taxane was administrated. (
  • Conclusions: CCRT is the most effective combination when RT is combined with CTx in the NCI-H520 cell line. (
  • Palbociclib (marketed as Ibrance by Pfizer) is known as the first new drug that in combination with hormonal therapy has proven to be very effective in post-menopausal women with estrogen receptor-positive breast cancer. (
  • Early drug studies demonstrating effective treatments of HbSS and HbSβ 0 thalassaemia, stimulated clinical trials to develop disease-specific therapies to induce fetal haemoglobin due to its ability to block HbS polymerization. (
  • These drug combinations have been more effective than any of the other previously available therapies. (
  • As a result, most chemotherapy drugs can't build up to the levels needed to be effective. (
  • The study, published online today in the New England Journal of Medicine, is the phase 3 study following phase 1 and phase 2 clinical trials that led to U.S. Food and Drug Administration approval of palbociclib in early 2015. (
  • The most recent case involves British company AstraZeneca, which recently started clinical trials for administration of immuno-anticancer drug, "Impinj" in combination with a new drug made in Korea, "Vactosertib. (
  • In July, SillaJen joined Regeneron, one of the top five U.S. biopharmaceutical companies, to start on domestic clinical trials for combination therapy for kidney cancer. (
  • The reason that new drugs developed in Korea receive much attention from global companies is that the competitiveness of these drugs have been proved through various clinical trials. (
  • Clinical trials have also been conducted to ensure efficacy and safety of these combinations before they are introduced into the market. (
  • Study selection criteria Randomized or quasi-randomized trials that compared methotrexate with any other DMARD or combination of DMARDs and contributed to the network of evidence between the treatments of interest. (
  • Cerebral Therapeutics' infusion therapy may offer a more efficacious and reliable approach to treating neurological diseases for which oral and I.V. infused medicines are not able to achieve adequate control and/or are limited by systemic toxicities. (
  • However, selection of the most efficacious combinations for each patient can be a daunting task. (
  • Subsequently, hydroxycarbamide proved efficacious in adults with SCA and was Food and Drug Administration (FDA)-approved in 1998. (
  • The study, known as Breast Cancer Trials of Oral Everolimus (BOLER0-2 ), found that combining everolimus, with hormonal therapy drug exemestane, resulted in a two-fold increase in progression-free survival for postmenopausal women who received prior endocrine therapy. (
  • For the study, fixed-dose combination of acetylsalicylic acid (ASA), paracetamol (acetaminophen), and caffeine was reviewed. (
  • It was obvious from the study that what one drug - acetylsalicylic acid (ASA), paracetamol (acetaminophen), and caffeine could not achieve on its own could be achieved when they were combined. (
  • This study reveals that this new system has a potential for drug delivery application in the future, especially for combination therapy. (
  • One study looked at the effect of subsidising ACT drugs for children under five years of age and three studies looked at subsidising ACT drugs for people of all ages. (
  • The study clarifies the potential of these types of drugs for treating diseases. (
  • This study was developed to determine if a combination of four drugs (flutamide, testolactone, reduced hydrocortisone dose, and fludrocortisone) can normalize growth in children with congenital adrenal hyperplasia. (
  • The REAL-2 study results support the growing body of evidence on the role of Xeloda as the cornerstone of combination chemotherapy," said Lars Birgerson, M.D., PhD, Vice President, Global Head Medical Affairs at Roche. (
  • Two asthma-related deaths were reported in the combination arm of the study and none in the single-therapy group, which is not statistically significant. (
  • This study will also examine if this combination is well tolerated by HIV-positive pregnant women and if a combination of 3TC plus ZDV is safe for newborns. (
  • The CombiRx study also provides a large dataset to analyze different aspects of the disease, such as potential biomarkers for prognosis and response to therapy. (
  • This is the first study in which the combination of a GLP-1 receptor agonist drug and the endobarrier intestinal device has been used to successfully treat diabetes and obesity. (
  • The combination seems to result in the best improvements in both," said study author Piya Sen Gupta, MBBS, BMedSci, MRCP, research fellow at King's College Hospital London and City Hospital Birmingham in the United Kingdom. (
  • However, limited data exist on whether initial combination therapy improves outcomes, which was the aim of this Italian study. (
  • The global Combination Therapy Drug market research report provides complete study and detail analysis of the market. (
  • This well-done study by Puolakka and colleagues highlights that not only does early aggressive combination DMARD therapy have a beneficial effect on joint damage, it has a favorable influence on work disability. (
  • Here, we demonstrate its improved performance over other response parameters especially in a leukemia patient case study, where differential DSS between patient and control cells enabled identification of both cancer-selective drugs and drug-sensitive patient sub-groups, as well as dynamic monitoring of the response patterns and oncogenic driver signals during cancer progression and relapse in individual patient cells ex vivo . (
  • A complete study of Combination Therapy Drug based on emerging and dominant market segments, major geographical regions, supply chain analysis, Combination Therapy Drug revenue analysis will drive important business decisions. (
  • Based on the dynamic Combination Therapy Drug market trends, developments taking place in Combination Therapy Drug, competitive study, growth opportunities, Combination Therapy Drug market will reflect huge development in coming years. (
  • All the crucial Combination Therapy Drug market factors leading to growth has been covered in this Combination Therapy Drug study. (
  • Reports on a study investigating the use of incentives in the form of prizes to motivate outpatients to stay in behavioral therapy and remain drug free. (
  • LONDON , Nov. 17, 2016 /PRNewswire/ -- Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. (
  • To minimize the non-specific toxicity of drug combination during cancer therapy, we prepared a new system synthesized from bacteria to deliver the anticancer drugs cytosine arabinoside (Ara-C) and daunorubicin (DNR). (
  • The drugs, which affect the structure and function of the cancer cell's DNA rather than the activity of its proteins, also slowed the growth of human lung cancer cells in mice. (
  • Mazur and Herner wondered whether tinkering with a cell's epigenetics could control the growth and proliferation of pancreatic cancer cells without causing many of the deleterious side effects seen by drugs that inhibit protein members of the Ras pathway, a cellular signaling cascade that controls cell growth, development and survival. (
  • Mazur tried eight drugs in combination with JQ1, each targeting either a known cancer-associated pathway or a step involved in epigenetics. (
  • Approved by the FDA in 1993, the drug cladribine offered hope for the then-fatal blood cancer called hairy cell leukemia, or HCL, and was soon expanded as a therapy for multiple sclerosis. (
  • For example, in cancer therapy, a physician often meets a patient having a genomic profile including more than five molecular aberrations. (
  • These anti-cancer mechanisms in turn pave the path for development of new drugs and strategies to tackle with the condition. (
  • The development of potential anti-cancer drugs mostly relies on tissue culture experiments performed on plastic culture dishes, also referred to as two-dimensional culture. (
  • Estrogen-receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer subgroup represents the largest proportion of breast cancer cases and is traditionally treated with therapies, like tamoxifen or letrozole, that target the hormone receptor pathway. (
  • The people were treated with a combination of palbociclib and letrozole, and had not received prior systemic therapy for their cancer. (
  • Combined estrogen/progestogen therapy, but not estrogen alone, increases the risk of breast cancer when used for more than three to five years. (
  • Anti-cancer drugs developed in Korea are receiving love calls from global pharmaceutical and biotechnology companies. (
  • It is a drug that kills cancer cells by enhancing the self-healing ability of the patient. (
  • The global pharmaceutical company BMS decided to use Pexa-Vec with its self-developed anti-cancer drug "Ipilimumab. (
  • In vitro experiments reveal that AdRGD-PGp53 sensitizes prostate cancer cells to each of the drugs tested, conferring increased levels of cell death. (
  • Debruyne F. Hormonal therapy of prostate cancer. (
  • Researcher Rosalie C. Sears says, "It's clear we're not going to find a single magic bullet that cures cancer but will instead need several drugs that target multiple vulnerabilities. (
  • Despite such awareness, the current epi-drug era has opened novel therapeutic avenues for various diseases beyond cancer. (
  • Here, we developed and implemented a quantitative scoring approach, named drug sensitivity score (DSS), which captures and integrates the multiparametric dose-response relationships into a single metric to identify selective drug response patterns between cancer and control cells, rather than scoring drug activity in cancer cells alone. (
  • ImmunoGen's lead product candidate, the clinical-phase mirvetuximab soravtansine (IMGN853), will be studied with Merck & Co.'s Keytruda ® (pembrolizumab) as a combination therapy for folate receptor alpha (FRα)-positive ovarian cancer. (
  • ImmunoGen said it will add the combination to its ongoing Phase IB/II FORWARD II trial, in which the company is assessing mirvetuximab soravtansine for FRα-positive ovarian cancer in separate combinations with other anticancer agents. (
  • In preclinical testing, an experimental drug for pancreatic cancer blocks the formation of microtubules in the cell, hindering growth. (
  • The drug, an experimental compound called PTC596 that had shown antitumor activity in mouse and human pancreatic cancer cells, seemed to have the right qualities: PTC596 has a durable half-life (most cancer drugs have a half-life of a few minutes to hours) and can evade a pump that many cancer cells use to expel drugs. (
  • Based on those studies, Olive, Eberle-Singh, and their collaborators tested PTC596 in combination with gemcitabine (a first-line drug for pancreatic cancer) in genetically engineered mice with an aggressive form of pancreatic cancer that is generally resistant to chemotherapy. (
  • In total, DrugCombDB includes 1,127,969 experimental data points wit quantitative dose response and concentrations of drug combinations covering 561 unique drugs and 104 human cancer cell lines, and 1,875 FDA approved or literature-supported drug combinations. (
  • Anti-Cancer Drugs. (
  • ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections than the chemotherapy combination, but with more hepatic toxi. (
  • Olaparib will provide similar outcomes but less toxicity than paclitaxel and that olaparib/cediranib combination might provide better outcomes. (
  • Chapters in this book explain methods to select combination drugs based on PK/PD evaluations followed by methods o reduce drug toxicity based on these evaluations. (
  • They are designed to empower biotech/pharma professionals from a business development, drug development or investment perspective. (
  • Proceeds from the financing will be used to progress the company's lead program to an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to enable further clinical development. (
  • People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center. (
  • On the contrary, prolonged and tedious development phase followed by high costs of drug development process are some of the factors that might restrain the growth of the market. (
  • Rising demand for drug combinational devices coupled with research and development initiatives will help the region to grow further at constant rate. (
  • Korean company SillaJen is also cooperating with a global company for development of combination therapy. (
  • This review mainly focuses on the development of a vinca alkaloid drug delivery system and the combination therapy. (
  • The AdRGD-PGp53 approach warrants further development for its application in gene therapy of prostate carcinoma. (
  • The development of combination drug therapies has been necessitated by the nature of complex diseases. (
  • The Combination Therapy Drug market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. (
  • A thorough analysis of Combination Therapy Drug based on the primary market segments, sub-segments, emerging market sectors, Combination Therapy Drug development trends, opportunities and threats to the market development has been evaluated. (
  • Comprehensive details related to Combination Therapy Drug market development during the forecast period, investment return analysis, technological advancement taking place in Combination Therapy Drug will assist all the market players for planning development strategies. (
  • This report also covers the Combination Therapy Drug marketing strategies followed by Combination Therapy Drug distributors analysis, potential buyers, marketing channels and Combination Therapy Drug development history. (
  • Combination Therapy Drug Market analysis based on top players, Combination Therapy Drug market gains, sales, product type, production capacity and gross margin analysis will favor the market development. (
  • The recommendations focus on a spectrum of basic discovery and translational research activities critical to the development of disease-modifying as well as symptomatic therapies across the disease continuum for the cognitive as well as neuropsychiatric symptoms of Alzheimer's disease, and they identify the types of infrastructures, resources, and new public private partnerships needed to successfully implement this translational agenda. (
  • Develop strategies to overcome intellectual property barriers to Alzheimer's disease drug development. (
  • There have been several FDA-approved radioimmunoconjugate therapies, including Bexxar, Lutathera, and Azedra, and development of new ARCs is an active area of investigation in the biotechnology and pharmaceutical industries. (
  • 14 Following the completion of single-agent Phase I and Phase II studies, the company has focused clinical development of 225 Ac-lintuzumab in mechanism-based clinical combinations. (
  • Thanks to the fast development of high-throughput screening (HTS) methods, the amount of available drug combination datasets has tremendously increased. (
  • Is systems pharmacology ready to impact upon therapy development? (
  • Describes investigations to advance the development of potential drug abuse relapse prevention agents by targeting specific receptors of the neurochemical serotonin. (
  • Our findings suggest that the combination of proteaseinhibitors and other anti-HIV medications can restore the immunesystem to a point where it can fight the CMV retinitis infection onits own," said Dr. Scott Whitcup, clinical director of NEI andfirst author of the JAMA letter. (
  • MRI findings also suggested that the IFN plus GA together were better in reducing new lesions and total lesion accumulation than either drug alone. (
  • The findings may lead to improvements in clinical combination chemotherapy. (
  • We hypothesize that using a potent antiretroviral such as Enfuvirtide during the induction phase of HAART therapy will lead to faster clearance of virus and infected cells, and lower numbe. (
  • Drug combination therapies are often referred to as "highly active antiretroviral therapies" ( HAART ). (
  • After an inadequate response to methotrexate, several treatments were statistically superior to oral methotrexate for ACR50 response: triple therapy, methotrexate plus hydroxychloroquine, methotrexate plus leflunomide, methotrexate plus intramuscular gold, methotrexate plus most biologics, and methotrexate plus tofacitinib. (
  • Combination of methotrexate and infliximab, followed by sulfasalazine, leflunomide, methotrexate with cyclosporine and prednisone, gold with methylprednisolone, and azathioprine with prednisone (group 4). (
  • Previous studies have shown that aggressive initial drug therapy with a combination of such antirheumatic drugs as methotrexate, hydroxychloroquine, and sulfasalazine in early RA leads to slower progression of joint damage than therapy with a single antirheumatic drug over the first 2 years ( 2 ). (
  • Combination antihypertensive drug therapy has long been an infrequently exercised therapeutic option in the difficult battle to achieve target blood pressure levels. (
  • The many benefits that will accrue from adoption of this therapeutic strategy include improved blood pressure control, fewer drug-induced side effects (including metabolic effects) and lower drug acquisition costs. (
  • After decades in which no novel therapeutic treatments were approved for acute myeloid leukemia (AML), the past few years have seen the approval of several groundbreaking therapies for the disease. (
  • Velcade is a "smart" drug known as a proteasome inhibitor that blocks the myeloma cells' waste disposal system, creating an accumulation of toxic compounds that poison the cell. (
  • The therapy will pair the PARP inhibitor olaparib with the chemotherapy drugs irinotecan (IRN) and temozolomide (TMZ). (
  • Gibbons and colleagues take aim at ZEB1 with a drug called mocetinostat, a histone deacetylase inhibitor previously shown to revert troublesome mesenchymal cells back to well-behaving epithelial cells. (
  • The drugs used are L-asparaginase and a MEK inhibitor. (
  • The integrase inhibitor/NRTI of drug combination segment is expected to account for a substantial share of the global demand for antiviral combination therapies in the near future. (
  • SAT-690: One Year Efficacy, Safety and Tolerability Outcomes of Endoscopic Duodenal Exclusion Using Endobarrier as an Adjunct to Glucagon-like Peptide-1 (GLP-1) Therapy in Suboptimally Controlled Type 2 Diabetes: A Randomised Controlled Trial. (
  • Based on comparison studies, these newer combinations might have provided bigger differences in CV outcomes. (
  • The use of anti-HIV drug combinations, when accompanied by anincrease in CD4 cell counts, may allow us to change standard treatmentfor CMV retinitis," Dr. Whitcup said. (
  • p = 0.350) were not significantly different before versus after antiplatelet-combination single-pill therapy. (
  • At this point, my doctor wanted to continue treatments with the Cytoxan/Rituxan combination for another three treatments. (
  • Other treatments for T-PLL include combining alemtuzumab with the drug pentostatin, the FMC drug combination (fludarabine, mitoxantrone, and cyclophosphamide) followed by intravenous alemtuzumab, and hematopoietic stem cell transplantation. (
  • It is important not to underestimate the complexity of the new drug treatments. (
  • It is necessary because in many cases, one drug cannot target all necessary points of intervention. (
  • The introduction of drug-eluting stents (DES) reduced the rates of restenosis after percutaneous coronary intervention (PCI) [ 1 ]. (
  • One drug usually cannot target all the necessary points of intervention. (
  • Because bacteria - especially Gram-negative strains - are becoming increasingly resistant to current antibiotics, investigators are studying the potential of combining two or more drugs to work together to combat resistant bacterial pathogens. (
  • Drug-resistant influenza is a significant threat to global public health. (
  • However, combination therapy offered a clear benefit by preventing the emergence and spread of drug-resistant viruses. (
  • XDR, extensively drug resistant. (
  • After VerifyNow P2Y12 and aspirin assays, the combination single pill of aspirin and clopidogrel was given and laboratory tests were repeated 6 weeks later. (
  • Concretely, the data sources include 1) high-throughput screening assays of drug combinations, 2) external databases, and 3) manual curations from PubMed literature. (
  • Adjuvant antiviral therapy cannot be recommended. (
  • The antiviral combination therapies market is set for a rapid growth over the forecast period. (
  • Antiviral combination therapies are medications formulated using a combination of two or more drugs to treat different viral diseases, including chronic infections such as hepatitis B, hepatitis C and Human Immunodeficiency Virus (HIV). (
  • In addition, the emphasis among leading companies on business-centric activities such as joint ventures, mergers and acquisitions, and ground-breaking product launches also adds momentum to the size of the global antiviral combination therapy industry. (
  • Companies are taking bold moves in the antiviral combination therapy market by increasing their paths to tackle COVID-19. (
  • Innovations in combination therapy trials have been fuelled by the increasing demand for antiviral drugs. (
  • He was also a founding editor of the medical journal, Antiviral Therapy. (
  • In 2006 he became Professor of Medicine at the Academic Medical Center, University of Amsterdam and Senior Scientific Advisor to the International Antiviral Therapy Evaluation Centre, Amsterdam. (
  • So Pawel had the idea to look for drug combinations that might have a synergistic effect. (
  • Subjects were identified in the Lombardy region National Health Service database (which includes more than 5 million individuals) who received at least one new prescription for an antihypertensive medication and no antihypertensive drug prescriptions in the preceding 10 years. (
  • Along with this, the research report also covers all the major players that are operating in the global Combination Therapy Drug market. (
  • Apart from this, the market research report also covers drivers and restraints for the global Combination Therapy Drug market and their impact on the demand and supply during the forecast period. (
  • In addition, the report also covers all the major players of the global Combination Therapy Drug market and its key offerings and solutions. (
  • Major regions and their revenue analysis covered in Combination Therapy Drug include North America, Europe, Japan, China, India, South East Asia . (
  • Thus, in addition to disabling major pro-survival proteins, the combination therapy also helps to unleash several additional proteins that promote apoptosis. (
  • After processing of various combinations according to the radiation dose and concentrations of chemotherapeutic agents, the level of cell survival was quantified by a MTT assay. (
  • 1 One of the most rapidly adopted agents is venetoclax (ABT-199), which results in favorable response rates and improved overall survival when used in combination with hypomethylating agents or low-dose cytarabine. (
  • We want to learn how to wipe out that alternative survival pathway at the beginning of therapy - to pull the rug out from under those cells right away. (
  • We show a significant 25 per cent reduction in the risk of disease progression with the combination of dabrafenib and trametinib over single-agent dabrafenib," says Assistant Professor Long. (
  • Further accounting for potential changes to the genetic profile during disease progression, the ability to optimize drug combinations for each patient is rapidly moving beyond the comprehension and capabilities of an individual physician. (
  • Coadministration of NNRTIs and PIs with AL could potentially cause complex pharmacokinetic drug interactions. (
  • When proceeding with adjunctive therapy, considerations should include choosing an agent with a different mechanism of action to that of the existing antiepileptic drug and avoiding unfavourable pharmacokinetic interactions (e.g. those related to hepatic metabolism and enzyme induction). (
  • Regarding drugs, hundreds of 2D, 3D, and even 4D molecular descriptors for medicines are now available. (
  • A subsequent AI application for the selection of drug therapy used an expert system was also devised, but in this case, a knowledge base of only around 100 rules (extracted from medical professionals) was used for selection of the best antimicrobial therapy [4]. (

No images available that match "drug therapy combination"